Literatur zu Buchteil V
Literatur zu Kap. 22
1.
2.
3.
4.
Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, Mulvany MJ: Evidence
for increased media thickness and increased neuronal amine uptake, but
depressed excitation contraction coupling in isolated resistance vessels from
essential hypertensives. Circ Res 1987, 61: 181–186
Alderman MH. A new model of risk: implications of increasing pulse
pressure and systolic blood pressure on cardiovascular disease. J Hypertens
1999, 17 (Suppl 5): S25–S28
Allemann Y, Weidmann P: Cardiovascular, metabolic and hormonal
dysregulations in normotensive offsprings of essential hypertension. J
Hypertens 1995, 13: 163–173
ALLHAT Collaborative Research Group. Major cardiovascular events in
hypertensive patients randomized to doxazosin vs chlorthalidone: the
5.
6.
7.
8.
antihypertensive and lipid-lowering treatment to prevent heart attack trial.
JAMA 2000,283: 1967–1975
Anderson EA, Sinkey CA, Lawton WJ, Mark AL: Elevated sympathetic
nerve activity in borderline hypertensive humans. Evidence from direct
intraneural recordings. Hypertension 1989, 14: 177–183
Asmar R, Benetos A, Pannier B, Agnes E et al.: Prevalence and circadian
variations of ST-segment depression and ist concomitant blood pressure
changes in asymptomatic, systemic hypertension. Am J Cardiol 1996, 77:
384–390
Assmann G, Schulte H: The prospective cardiovascular Münster
(PROCAM) study: prevalence of hyperlipidemia in persons with
hypertension and/or diabetes mellitus and the relationship to coronary artery
disease. Am Heart J 1988, 116: 1713–1724
Beilin LJ (1988) Epitaph to essential hypertension – a preventable disorder
of known aetiology. J Hypertens 6: 85–94
9.
10.
11.
12.
13.
14.
Bianchi G, Cusi D, Barlassina C et al: Renal dysfunction as a possible cause
of essential hypertension in predisposed subjects. Kidney Intern 1983, 23:
870–875
Bianchi S, Bigazzi R, Campese VM: Microalbuminuria in essential
hypertension: signifiance, pathophysiology, and therpeutic implications. Am
J Kidney Dis 1999, 34: 973–995
Blaustein MP, Hamlyn JM: Pathogenesis of essential hypertension.
Hypertension 1991, 18 (5 Suppl): III-184–III-195
Boon D, Piek JJ, van Montfrans GA: Silent ischaemia and hypertension. J
Hypertens 2000, 18: 1355–1364
Channik BJ, Adlin EV,Marks D: Suppressed plasma renin activity in
Hypertension. Arch Intern Med 1969, 123: 131–138
Dawber TR: The Framinham Study. Harvard University Press, Cambridge,
MA, 1980
15.
16.
17.
18.
19.
20.
Deutsche Liga zur Bekämpfung des hohen Blutdruckes: Empfehlungen zur
Diagnostik der Hypertonie. Heidelberg 1991, 4. Auflage
Deutsche Liga zur Bekämpfung des hohen Blutdruckes: Empfehlungen zur
Hochdruckbehandlung. Heidelberg 1999,. 15. Auflage
Dickerson JE, Hingoran AD, Ashby MJ, Palmer CR, Brown MJ:
Optimisation of antihypertensive treatment by crossover rotation of four
major classes. Lancet 1999, 353: 2008–2013
Esler M, Ferrier C, Lambert G, Eisenhofer G, Cox H, Jennings G:
Biochemical evidence of sympathetic hyperactivity in human hypertension.
Hypertension 1991, 17 (Suppl III): III-29–III-35
Ferrannini E: Metabolic abnormalities of hypertension. Hypertension 1991,
18: 636–639
Folkow B: Integration of hypertension research in the aera of molecular
biology. J Hypertens 1995, 13: 5–18
21.
22.
23.
24.
25.
Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH et al.:
Prevention of dementia in randomised double-blind placebo-controlled
Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352: 1347–
1351
Frank E : Bestehen Betziehungen zwischem chromaffinem System und der
chronischen Hypertonie des Menschen? Ein kritischer Beitrag zur Lehre von
der pathophysiologischen Bedeutung des Adrenalins. Dtsch Arch Klin Med
1911, 193: 397–408
Franz I-W: Ergometrische Untersuchungen. In: Klaus D (Hrsg) Manuale
hypertonologicum. Dustri-Verlag, Deisenhofen 1997: IV.–3.3
Gordon T, Kannel WB: Drinking and ist relation to smoking, blood
pressure, blood lipids and uric acid. Arch Intern Med 1983, 143: 1366–1374
Guidelines Subcommittee 1999 World Health Organization – International
Society of Hypertension: Guidelines for the Management of Hypertension. J
Hypertens 1999, 17: 151–184
26.
27.
28.
29.
30.
31.
Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison
Committee: Guidelines for the management of mild hypertension. J
Hypertens 1993, 11: 905–918
Guyton AC, Coleman TG, Cowley, AW Scheel KW, Manning RD, Norman
RA: Arterial pressure regulation. Am J Med 1972, 52: 584–594
Hamlyn JM, Manunta P: Ouabain, digitalis-like factors and hypertension. J
Hypertens 1992, 10 (Suppl 7): S99–S111
Henry JP, Grim CE : Psychosocial mechanism of primary hypertension. J
Hypertens 1990, 8: 783–793
Taddei S, Virdis A, Mattei P, Arsilli F, Salvetti A (1992) Endotheliumdependent forearm vasodilatation is reduced in normotensive subjects with a
family history of hypertension. J Cardiovasc Pharmacol 1992, 20 (Suppl
12): S193–S195
Beilin LJ (1988) Epitaph to essential hypertension – a preventable disorder
of known aetiology. J Hypertens 6: 85–94
32.
33.
34.
35.
36.
37.
Skarfors ET, Lithell HO, Selinus I: Risk factors for the development of
hypertension. J Hypertens 1991, 9: 217–223
Julius, S, Hansson L, Andren L, Svensson A: Borderline hypertension. Acta
Med Scand 1980, 208: 481–489
Keil U, Remmers A, Chambless L, Hense HW, Stieber J, Lauck A:
Epidemiologie des Bluthochdrucks. Häufigkeit, Verteilung, Bekanntheitsund Behandlungsgrad der Hypertonie in der Hansestadt Lübeck. Münch
Med Wochenschr 1986, 128: 424–429
Kilander L, Nyman H, Boberg M, Lithell H: The association between low
diastolic blood pressure in middle age and cognitive function in old age. A
population-based study. Age Ageing 2000, 29: 243–248
Klag MJ, Whelton PK, Randall BL, Neaton JD et al.: Blood pressure and
end-stage renal disease in men. N Eng J Med 1996, 334: 13–18
Klaus D. Atherosklerose und Arteriosklerose als Hochdruckfolgen. Nierenund Hochdruckkrankheiten 2000, 29: 1–16
38.
39.
40.
41.
42.
43.
Klaus D: Akute hypertensive Enzephalopathie. Intensivmedizin 1983, 20:
45–51
Klaus D: Ätiopathogenese der essentiellen Hypertonie. In: Klaus D (Hrsg)
Manuale hypertonologicum. Dustri-Verlag, Deisenhofen 1997: III-11, 1–50
Klaus D: Vorschlag zur Einteilung und Klassifikation der chronischen
arteriellen Hypertonie. Dtsch Med Wochenschr 1987, 112: 483–484
Kremmer S, Selbach JM, Schäfers RF, Philipp T, Steuhl K: Das
kardiovaskuläre Risikoprofil bei der Progression der Glaukomerkrankung.
Dtsch Ärztebl 97, C 1704-C 1708
Laurenzi M, Mancini M, Menotti A, Stamler J, Stamler R, Zanchetti A et al:
Multiple risk factors in hypertension: results from the Gubbio study. J
Hypertens 1990, 8 (Suppl 1) S7–S12
Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A: Highormal blood pressure progression to hypertension in the Framingham Heart
Study. Hypertension 1991, 17: 22–27
44.
45.
46.
47.
48.
49.
Leonetti G, Cuspidi C, Facchini M, Stramba-Badiale M: Is systolic pressure
a better target for antihypertensive treatment than diastolic pressure? J
Hypertens 2000, 18 (Suppl 3): S13–S20
Levine B: Treatment of hypertension in the elderly. Clin Ther 1994, 16:
723–751
Lifton RP, Jeunemaitre X: Finding genes that cause human hypertension. J
Hypertens 1993, 11: 231–236
Lohmann FW: Essentielle Hypertonie. In: Klaus D (Hrsg) Manuale
hypertopnologicum. Dustri-Verlag, Deisenhofen, 1997, V.1
Lüscher TF: The endothelium in hypertension: bystander, target or
mediator. J Hypertens 1994, 12 (Suppl 10) S105–S116
MacMahon S, Peto R, Cutler J, Collins R, Sorlie P et al: Blood pressure,
stroke, and coronary heart disease. Part I. Prolonged differences in blood
pressure: prospective observational studies corrected for the regression
dilution bias. Lancet 1990, 335: 765–774
50.
51.
52.
53.
54.
55.
Mancini GBJ, Henry GC, Macaya et al: Angiotensin-converting enzyme
inhibition with qinapril improves endothelial vasomotor dysfunction in
pathients with coronary artery disease (TREND). Circulation 1996, 94: 258–
265
Maranon G: Über Hypertonie und Zuckerkrankheit. Zentralbl Inn Med
1922, 43: 169–176
Masia R, Pena A, Marrugat J, Sala J et al.: High prevalence of
cardiovascular risk factors in Gerona, Spain, a province with low
myocardial infarction incidence. J Epidemiol Community Health 1998, 52:
707–715
Medical Research Council Working Party: MRC trial of treatment of mild
hypertension. Principal results. Brit Med J 1985, 291: 97–104
Messerli FH: The age factor in hypertension. Hosp Pract 1986, 15: 103–112
Most E, Lehmann K, Blummer E, Letzel H, Schultz H: Behandlung der
essentiellen Hypertonie. Therapiewoche 1987, 47: 3075–3083
56.
57.
58.
59.
60.
Okosun IS, Prewitt TE, Cooper RS: Abdominal obesity in the United States.
Prevalence and atributable risk of hypertension. J Hum Hypertens 1999, 13:
425–430
O'Leary DH, Polak JF, Kronmal RA et al. for the Cardiovascular Health
Study Group: Carotid-artery intima and media thickmen as a risk factor for
myocardial infarction and stroke in older adultes. N Engl J Med 1999, 340:
14–22
Pfaffenbarger RS Jr, Robert PH, Hyde T et al: The association changes in
physical activity and other life style characteristics with mortality among
men. N Eng J Med 1993, 328: 538–545
Pickering GW: Hypertension. Definitions, natural histories and
consequences. Am J Med 1972, 52: 570–583
Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH:
How common is white coat hypertension? JAMA 1988, 259: 225–228
61.
62.
63.
64.
65.
66.
67.
Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:
1595–1607
Report of the Management Committee: The Australian therapeutic trial in
mild hypertension. Lancet 1980, I: 1261–1267
Rosa TT, Palatini P: Clinical value of microalbuminuria in hypertension. J
Hypertens 2000, 18: 645–654
Ross R: The pathogenesis of atherosclerosis. N Engl J Med 1986, 314: 488–
500
Safar ME, Levy BI, Laurent S, London GM: Hypertension and the arterial
system: clinical and therapeutic aspects. J Hypertens 1990, 8 (Suppl 7):
S113–S119
Sagie A, Larson MG, Levy D: The natural history of borderline isolated
systolic hypertension N Engl J Med 1993, 329: 1912
Saskawa O, Fujii S, Nogi O, Shimura M et al: A study of long-term
observations in borderline hypertension. Jpn Circ J 1983, 47: 300–308
68.
69.
70.
71.
72.
Schiffrin EL, Deng LY, Larochelle P: Effects of a beta blocker or a
converting enzyme inhibitor on resistance arteries in essential hypertension.
Hypertension 1994, 23: 83–91
Schröder S, Enderle MD, Meisner C, Baumbach A et al.:
Ultraschallmessung der Endothelfunktion der Arteria brachialis bei
Verdacht auf eine koronare Herzkrankheit. Dtsch Med Wochenschr 1999,
124: 886–890
Skarfors ET, Lithell HO, Selinus I: Risk factors for the development of
hypertension. J Hypertens 1991, 9: 217–223
Skoog I, Lernfelt B, Landahl S, Palmertz B et al.: 15-year longitudinal study
of blood pressure and dementia. Lancet 1996, 347: 1141–1145
Sleight P: Role of the barorecepctor reflexes in circulatory control with
particular reference to hypertension. Hypertension 1991, 18 (Suppl III): III31–III-34
73.
74.
75.
76.
77.
Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic, and
cardiovascular risk. US Population data. Arch Intern Med 1993, 153: 598–
615
Strasser T, Dowd JE: Mild hypertension in the Community. Findings from
the WHO Cooperative Community Control Project. In Gross F, Strasser T
(eds) Mild hypertension, Raven, New York 1983: 97–105
Struijker Boudier HAJ, leNoble JLML, Messing MWJ, Huijberts MSP,
leNoble FAC, van Essen H: The microcirculation and hypertension. J
Hypertens 1992, 10 (Suppl 7): S147–S156
Sullivan JM: Salt sensitivity. Hypertension 1991, 17 (Suppl I): I–61-I–68
Taddei S, Virdis A, Mattei P, Arsilli F, Salvetti A (1992) Endotheliumdependent forearm vasodilatation is reduced in normotensive subjects with a
family history of hypertension. J Cardiovasc Pharmacol 1992, 20 (Suppl
12): S193–S195
78.
79.
80.
81.
82.
83.
The Intersalt Cooperative Research Group: Intersalt: an international study
of electrolyte excretion and blood pressure. BMJ 1988, 297: 319–328
The MRFIT Research Group: Multiple risk factor intervention trial, Risk
factor changes and mortality results. JAMA 1982, 248: 1465–1477
Tobian L: Salt and hypertension. Hypertension 1991, 17 (Suppl I): I–52-I–
58
Trenkwalder P, Ruland D, Stender M, Gebhard J, Trenkwalder C, Lydtin H,
Hense HW: Prevalence, awareness, treatment and control of hypertension in
a population over the age of 65 years (STEPHY). J Hypertens 1994, 12:
709–716
United States Renal Data System: Excerpts from the United States Renal
Data System. Am J Kidney Dis 1994, 24 (Suppl 2): S12–S17
van Zwieten PA, Safar M, Laurent S, Pfaffendorf M, Hendriks MGC,
Bruning TB: New insights into the role of endothelial dysfunction in
hypertension. J Hypertens 1995, 13: 713–716
84.
85.
86.
87.
88.
89.
Vanhoutte PM: Endothelium and control of vascular function. Hypertension
1989, 13: 658–667
Veterans Administration Cooperative Study Group on Antihypertensive
Agents. Effects of treatment on morbidity in hypertension. Results in
patients with diastolic pressure averaging 115 trough 129 mmHg. JAMA
1967, 202: 116–121
Weber MA, Smith DHG, Neutel JM, Graettinger WFD: Arterial properties
of early hypertension. J Human Hypertension 1991, 5: 417–423
WHO Monica Project: Geographic Variation in Mortality from
Cardiovascular Diseases. Wld Hlth Statist Quart 1987, 40: 171–184
Williams GH, Hollenberg NK: Are non-modulating patients with essential
hypertension a distinct subgroup? Am J Med 1985, 79 (Suppl 3C): 3–9
Williams RR, Hunt SC, Wu LL, Hopkins PN et al: Concordant
dyslipidemia, hypertension and early coronary disease in Utah families. Klin
Wochenschr 1990, 68 (Suppl XX): 53–59
90.
91.
Wilson PWF: Established risk factors and coronary artery disease. The
Framingham study. Am J Hypertension 1994, 7: 7S–12S
Zweifler AJ, Shabab TS: Pseudohypertension. J Hypertens 1993, 11: 1–6
Literatur zu Kap. 23
Literatur zu Kap. 23.1
1.
Deutsche Hypertonie Gesellschaft/Deutsche Liga zur Bekmpfung des
hohen Blutdrucks: Leitlinien zur Hypertoniebehandlung – Niere und
Bluthochdruck. 1996
2.
Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M,
Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-convertingenzyme inhibitor benazepril on the progression of chronic renal
insufficiency. The Angiotensin-Converting-Enzyme Inhibition in
Progressive Renal Insufficiency Study Group. N Engl J Med 1996;
334: 939–945
3.
Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R,
Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C,
Fagard R. Effects of calcium-channel blockade in older patients with
diabetes and systolic hypertension. Systolic Hypertension in Europe
4.
5.
6.
7.
Trial Investigators. N Engl J Med 1999; 340: 677–684
Effects of ramipril on cardiovascular and microvascular outcomes in
people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study
Investigators. Lancet 2000 Jan 22; 355 (9200): 253–9
National Insititutes of Health. The Sixth Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure . NIH Publication No 98–4080, 1997
Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa
P, Steffes MW, Striker GE, Viberti GC. Prevention of diabetic renal
disease with special reference to microalbuminuria. Lancet 1995; 346:
1080–1084
Randomised placebo-controlled trial of effect of ramipril on decline in
glomerular filtration rate and risk of terminal renal failure in
proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo
8.
9.
10.
11.
Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349:
1857–1863
Ismail N, Becker B Strzelczyk P, Ritz E. Renal disease and
hypertension in non-insulin-dependent diabetes mellitus. Kidney Int
1999; 55: 1–28
Jacobson HR, Striker GE. Report on a workshop to develop
management recommendations for the prevention of progression in
chronic renal disease. Am J Kidney Dis 1995; 25: 103–106
Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood
pressure and diastolic left ventricular malfunction in patients with
glomerulonephritis. Kidney Int 1996; 50: 1321–1326
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW,
Striker G. The effects of dietary protein restriction and blood-pressure
control on the progression of chronic renal disease. Modification of
Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877–884
12.
13.
14.
15.
16.
Klahr S. The kidney in hypertension – villain and victim. N Engl J
Med 1989; 320: 731–733
Bakris GL. The role of combination antihypertensive therapy and the
progression of renal disease hypertension: looking toward the next
millennium. Am J Hypertens 1998; 11: 158S-162S
World Health Organization International Society of Hypertension.
Journal of Hypertension 1999; 17 (1): 151–183
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the collaborative
study group. The effect of angiotensin-converting-enzyme inhibition
on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462
Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M,
Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-convertingenzyme inhibitor benazepril on the progression of chronic renal
insufficiency. The Angiotensin-Converting-Enzyme Inhibition in
Progressive Renal Insufficiency Study Group. N Engl J Med 1996;
17.
18.
19.
20.
334: 939–945
Randomised placebo-controlled trial of effect of ramipril on decline in
glomerular filtration rate and risk of terminal renal failure in
proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo
Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349:
1857–1863
Maschio G et al. Nephrol Dial Transplant 2002; 17 (S11): 47–49
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of
an angiotensin-converting-enzyme inhibitor, ramipril, on
cardiovascular events in high-risk patients. The Heart Outcomes
Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:
145–153
Parving H-H, Lehnert H, Brchner-Mortensen J, Gomis R, Anderson S,
Arner P, for the irbesartan in patients with type 2 diabetes and
microalbuminuria study group. The effect of irbesartan on the
21.
22.
23.
development of diabetic nephropathy in patients with type 2 diabetes.
N Engl J Med 2001; 345: 870–878
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB,
Ritz E, Atkins RC, Rohde R, Raz I, for the collaborative study group.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan
in patients with nephropathy due to type 2 diabetes. N Engl J Med
2001; 345: 851–860
Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE,
Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the
RENAAL Study Investigators. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med 2001; 345: 861–869
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U,
Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O,
Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the
24.
LIFE study group. Cardiovascular morbidity and mortality in the
Losartan Intervention For Endpoint reduction in hypertension study
(LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–
1003.
Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire
U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, LederballePedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P,
Edelman J, Snapinn S, for the LIFE study group. Cardiovascular
morbidity and mortality in patients with diabetes in the Losartan
Intervention for Endpoint reduction in hypertension study (LIFE): a
randomised trial against atenolol. Lancet 2002; 359: 1004–1010
Literatur zu Kap. 23.2
1.
Appel RG, Bleyer AJ, Reavis S and Hansen KJ (1995) Renovascular
disease in older patients beginning renal replacement therapy. Kidney Int,
48: 171–176
2.
Aurell M and Jensen G (1997) Treatment of renovascular hypertension.
Nephron, 75: 373–383
3.
Baboolal K, Evans C and Moore RH (1998) Incidence of end-stage renal
disease in medically treated patients with severe bilateral atherosclerotic
renovascular disease. Am J Kidney Dis, 31: 971–977
4.
Berger ED, Bader BD, Bosker J, Risler T and Erley CM (2001) Contrast
media-induced kidney failure cannot be prevented by hemodialysis. Dtsch
Med Wochenschr, 126: 162–166
5.
Berguer R and Hwang NH (1974) Critical arterial stenosis: a theoretical
and experimental solution. Ann Surg, 180: 39–50
6.
Beutler JJ, Van Ampting JM, Van De Ven PJ, Koomans HA, Beek FJ,
7.
8.
9.
Woittiez AJ and Mali WP (2001) Long-term effects of arterial stenting on
kidney function for patients with ostial atherosclerotic renal artery stenosis
and renal insufficiency. J Am Soc Nephrol, 12: 1475–1481
Blum U, Krumme B, Flugel P, Gabelmann A, Lehnert T, Buitrago-Tellez
C, Schollmeyer P and Langer M (1997) Treatment of ostial renal-artery
stenoses with vascular endoprostheses after unsuccessful balloon
angioplasty. N Engl J Med, 336: 459–465
Bonelli FS, McKusick MA, Textor SC, Kos PB, Stanson AW, Johnson
CM, Sheedy PF, 2nd, Welch TJ and Schirger A (1995) Renal artery
angioplasty: technical results and clinical outcome in 320 patients. Mayo
Clin Proc, 70: 1041–1052
Boudewijn G, Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de
Leeuw PW and van Engelshoven JM (2001) Diagnostic tests for renal
artery stenosis in patients suspected of having renovascular hypertension:
a meta-analysis. Ann Intern Med, 135: 401–411
10.
11.
12.
13.
Burdick L, Airoldi F, Marana I, Giussani M, Alberti C, Cianci M, Lovaria
A, Saccheri S, Gazzano G and Morganti A (1996) Superiority of
acceleration and acceleration time over pulsatility and resistance indices as
screening tests for renal artery stenosis. J Hypertens, 14: 1229–1235
Caps MT, Perissinotto C, Zierler RE, Polissar NL, Bergelin RO, Tullis
MJ, Cantwell-Gab K, Davidson RC and Strandness DE, Jr. (1998)
Prospective study of atherosclerotic disease progression in the renal artery.
Circulation, 98: 2866–2872
Cohn EJ, Jr., Benjamin ME, Sandager GP, Lilly MP, Killewich LA and
Flinn WR (1998) Can intrarenal duplex waveform analysis predict
successful renal artery revascularization? J Vasc Surg, 28: 471–80;
discussion 480–481
Connolly JO, Higgins RM, Walters HL, Mackie AD, Drury PL, Hendry
BM and Scoble JE (1994) Presentation, clinical features and outcome in
different patterns of atherosclerotic renovascular disease. Qjm, 87: 413–
14.
15.
16.
17.
421
Danielson M, Dammstrom B (1981) The prevalence of secondary and
curable hypertension. Acta Med Scand, 209: 451–455
Darling RC, 3rd, Kreienberg PB, Chang BB, Paty PS, Lloyd WE, Leather
RP and Shah DM (1999) Outcome of renal artery reconstruction: analysis
of 687 procedures. Ann Surg, 230: 524–530; discussion 530–532
De Cobelli F, Mellone R, Salvioni M, Vanzulli A, Sironi S, Manunta P,
Lanzani C, Bianchi G and Del Maschio A (1996) Renal artery stenosis:
value of screening with three-dimensional phase- contrast MR
angiography with a phased-array multicoil. Radiology, 201: 697–703
De Cobelli F, Vanzulli A, Sironi S, Mellone R, Angeli E, Venturini M,
Garancini MP, Quartagno R, Bianchi G and Del Maschio A (1997) Renal
artery stenosis: evaluation with breath-hold, three-dimensional, dynamic,
gadolinium-enhanced vs. three-dimensional, phase-contrast MR
angiography. Radiology, 205: 689–695
18.
19.
20.
21.
Dondi M, Fanti S, De Fabritiis A, Zuccala A, Gaggi R, Mirelli M, Stella
A, Marengo M, Losinno F and Monetti N (1992) Prognostic value of
captopril renal scintigraphy in renovascular hypertension. J Nucl Med, 33:
2040–2044
Dorros G, Jaff M, Mathiak L, Dorros, II, Lowe A, Murphy K and He T
(1998) Four-year follow-up of Palmaz-Schatz stent revascularization as
treatment for atherosclerotic renal artery stenosis. Circulation, 98: 642–
647
Elkohen M, Beregi JP, Deklunder G, Artaud D, Mounier-Vehier C and
Carre AG (1996) A prospective study of helical computed tomography
angiography vs. angiography for the detection of renal artery stenoses in
hypertensive patients. J Hypertens, 14: 525–528
Elliott WJ, Martin WB and Murphy MB (1993) Comparison of two
noninvasive screening tests for renovascular hypertension. Arch Intern
Med, 153: 755–764
22.
23.
24.
25.
26.
Farmer CK, Cook GJ, Blake GM, Reidy J and Scoble JE (1999) Individual
kidney function in atherosclerotic nephropathy is not related to the
presence of renal artery stenosis. Nephrol Dial Transplant, 14: 2880–2884
Frauchiger B, Zierler R, Bergelin RO, Isaacson JA and Strandness DE, Jr.
(1996) Prognostic significance of intrarenal resistance indices in patients
with renal artery interventions: a preliminary duplex sonographic study.
Cardiovasc Surg, 4: 324–3230
Frei U and Schober-Halstenberg HJ (1999) Annual Report of the German
Renal Registry 1998. QuaSi-Niere Task Group for Quality Assurance in
Renal Replacement Therapy. Nephrol Dial Transplant, 14: 1085–1089
Gerhardt (1996) Pathophysiology of renovascular Hypertension. In: K.D.
Calligaro, MJ; Dean, RH (ed.), Modern Management of renovascular
hypertension and renal salvage, pp. 3–15, Williams&Wilkins, Baltimore,
Philadelphia, London
Goldblatt H (1934) Studies on experimental hypertension I. The
27.
28.
29.
30.
production of persistent elevation of systolic blood pressure by means of
renal ischemia. J Exp Med, 59: 347
Goncharenko V, Gerlock AJ, Jr., Shaff MI and Hollifield JW (1981)
Progression of renal artery fibromuscular dysplasia in 42 patients as seen
on angiography. Radiology, 139: 45–51
Gottlieb RH, Lieberman JL, Ghaed VN, Grossman EB, Waldman DL,
Azodo MV, Watt GH, Robinette WB and Carson NL (1996) Preliminary
assessment of captopril sonography in screening for renal artery stenosis.
Acad Radiol, 3: 57–62
Greco BA and Breyer JA (1996) The natural history of renal artery
stenosis: who should be evaluated for suspected ischemic nephropathy?
Semin Nephrol, 16: 2–11
Gross CM KJ, Weingartner O, Uhlich F, Luft FC, Waigand J, Dietz R.
(2001) Determination of renal arterial stenosis severity: comparison of
pressure gradient and vessel diameter. Radiology, 220 (3): 751–756
31.
32.
33.
34.
35.
Hansen KJ (1994) Prevalence of ischemic nephropathy in the
atherosclerotic population. Am J Kidney Dis, 24: 615–621
Hansen KJ, Starr SM, Sands RE, Burkart JM, Plonk GW, Jr. and Dean RH
(1992) Contemporary surgical management of renovascular disease. J
Vasc Surg, 16: 319–30; discussion 330–331
Harding MB, Smith LR, Himmelstein SI, Harrison K, Phillips HR,
Schwab SJ, Hermiller JB, Davidson CJ and Bashore TM (1992) Renal
artery stenosis: prevalence and associated risk factors in patients
undergoing routine cardiac catheterization. J Am Soc Nephrol, 2: 1608–
1616
Henry M, Amor M, Henry I, Ethevenot G, Tzvetanov K, Courvoisier A,
Mentre B and Chati Z (1999) Stents in the treatment of renal artery
stenosis: long-term follow-up. J Endovasc Surg, 6: 42–51
Hetzel GR, Hollenbeck M, Voiculescu A, Malms J, Cohnen M, Willers R,
Modder U and Grabensee B (2000) Effect of acute intravenous ace-
36.
37.
38.
39.
inhibition on the intrarenal doppler flow characteristics in hypertensive
patients with and without unilateral renal artery stenosis. Clin Exp
Hypertens, 22: 571–581
Hollenbeck M, Voiculescu A, Hetzel GR, Sandmann W, Modder U and
Grabensee B (2002) Arteriosclerotic renal artery stenosis. Significance,
diagnosis and therapy options. Med Klin, 97: 335–343
Imanishi M, Akabane S, Takamiya M, Kawamura M, Matsushima Y,
Kuramochi M and Omae T (1992) Critical degree of renal arterial stenosis
that causes hypertension in dogs. Angiology, 43: 833–842
Killen DA and Oh SU (1968) Quantitation of the severity of arterial
stenosis by pressure gradient measurement. Am Surg, 34: 341–349
Koch JA, Plum J, Grabensee B and Modder U (2000) Prostaglandin E1: a
new agent for the prevention of renal dysfunction in high risk patients
caused by radiocontrast media? PGE1 Study Group. Nephrol Dial
Transplant, 15: 43–49
40.
41.
42.
43.
44.
45.
Kotval PS (1989) Doppler waveform parvus and tardus. A sign of
proximal flow obstruction. J Ultrasound Med, 8: 435–440
Krumme B, Blum U, Schwertfeger E, Flugel P, Hollstin F, Schollmeyer P
and Rump LC (1996) Diagnosis of renovascular disease by intra- and
extrarenal Doppler scanning. Kidney Int, 50: 1288–1292
Krumme B and Mann JF (2001) Atherosclerotic renal artery stenosis in
2001–are we less confused than before? Nephrol Dial Transplant, 16:
2124–2127
Kutkuhn B, Godehardt E, Kunert J, Torsello G and Grabensee B (1991)
Validity of the captopril test for identifying correctable unilateral
renovascular hypertension. Clin Exp Hypertens A, 13: 143–157
Laragh JH (1977) The renin system in essential, renovascular and
adrenocortical hypertension: an overview. Adv Nephrol Necker Hosp, 7:
157–189
Leertouwer TC, Gussenhoven EJ, Bosch JL, van Jaarsveld BC, van Dijk
46.
47.
48.
49.
LC, Deinum J and Man In 't Veld AJ (2000) Stent placement for renal
arterial stenosis: where do we stand? A meta- analysis. Radiology, 216:
78–85
Lewin A, Blaufox MD, Castle H, Entwisle G and Langford H (1985)
Apparent prevalence of curable hypertension in the Hypertension
Detection and Follow-up Program. Arch Intern Med, 145: 424–427
Loubeyre P, Revel D, Garcia P, Delignette A, Canet E, Chirossel P, Genin
G and Amiel M (1994) Screening patients for renal artery stenosis: value
of three- dimensional time-of-flight MR angiography. AJR Am J
Roentgenol, 162: 847–852
Mailloux LU, Napolitano B, Bellucci AG, Vernace M, Wilkes BM and
Mossey RT (1994) Renal vascular disease causing end-stage renal disease,
incidence, clinical correlates, and outcomes: a 20-year clinical experience.
Am J Kidney Dis, 24: 622–629
Muller FB, Sealey JE, Case DB, Atlas SA, Pickering TG, Pecker MS,
50.
51.
52.
53.
Preibisz JJ and Laragh JH (1986) The captopril test for identifying
renovascular disease in hypertensive patients. Am J Med, 80: 633–644
Nelemans PJ, Kessels AG, De Leeuw P, De Haan M and van Engelshoven
J (1998) The cost-effectiveness of the diagnosis of renal artery stenosis.
Eur J Radiol, 27: 95–107
Olbricht CJ, Paul K, Prokop M, Chavan A, Schaefer-Prokop CM, Jandeleit
K, Koch KM and Galanski M (1995) Minimally invasive diagnosis of
renal artery stenosis by spiral computed tomography angiography. Kidney
Int, 48: 1332–1337
Olin JW, Piedmonte MR, Young JR, DeAnna S, Grubb M and Childs MB
(1995) The utility of duplex ultrasound scanning of the renal arteries for
diagnosing significant renal artery stenosis. Ann Intern Med, 122: 833–
838
Paulsen D, Klow NE, Rogstad B, Leivestad T, Lien B, Vatne K and
Fauchald P (1999) Preservation of renal function by percutaneous
54.
55.
56.
57.
58.
transluminal angioplasty in ischaemic renal disease. Nephrol Dial
Transplant, 14: 1454–1461
Pedersen EB (2000) New tools in diagnosing renal artery stenosis. Kidney
Int, 57: 2657–2677
Pickering TB, JD (2000) Renovascular hypertension and ischemic
nephropathy. In: B. Brenner (ed.), The Kidney, pp. 2007–2031, W.B.
Saunders Company
Plouin PF, Chatellier G, Darne B and Raynaud A (1998) Blood pressure
outcome of angioplasty in atherosclerotic renal artery stenosis: a
randomized trial. Essai Multicentrique Medicaments vs Angioplastie
(EMMA) Study Group. Hypertension, 31: 823–829
Prokop M, Schaefer-Prokop C and Galanski M (1997) Spiral CT
angiography of the abdomen. Abdom Imaging, 22: 143–153
Radermacher J and Brunkhorst R (1998) Diagnosis and treatment of
renovascular stenosis–a cost-benefit analysis. Nephrol Dial Transplant, 13:
59.
60.
61.
62.
2761–2767
Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ,
Galanski M, Koch KM and Haller H (2001) Use of Doppler
ultrasonography to predict the outcome of therapy for renal-artery stenosis.
N Engl J Med, 344: 410–417
Radermacher J, Chavan A, Schaffer J, Stoess B, Vitzthum A, Kliem V,
Rademaker J, Bleck J, Gebel MJ, Galanski M and Brunkhorst R (2000)
Detection of significant renal artery stenosis with color Doppler
sonography: combining extrarenal and intrarenal approaches to minimize
technical failure. Clin Nephrol, 53: 333–343
Radermacher J, Weinkove R and Haller H (2001) Techniques for
predicting a favourable response to renal angioplasty in patients with
renovascular disease. Curr Opin Nephrol Hypertens, 10: 799–805
Reiher L, Langzeitergebnisse nach gefäßchirurgischer Rekonstruktion der
Nierenarterien, Habilitationsarbeit (2001)
63.
64.
65.
66.
67.
Riehl J, Schmitt H, Bongartz D, Bergmann D and Sieberth HG (1997)
Renal artery stenosis: evaluation with colour duplex ultrasonography.
Nephrol Dial Transplant, 12: 1608–1614
Safian RD and Textor SC (2001) Renal-artery stenosis. N Engl J Med,
344: 431–442
Sawicki PT, Kaiser S, Heinemann L, Frenzel H and Berger M (1991)
Prevalence of renal artery stenosis in diabetes mellitus–an autopsy study. J
Intern Med, 229: 489–492
Schoenberg SO, Knopp MV, Londy F, Krishnan S, Zuna I, Lang N, Essig
M, Hawighorst H, Maki JH, Stafford-Johnson D, Kallinowski F,
Chenevert TL and Prince MR (2002) Morphologic and functional
magnetic resonance imaging of renal artery stenosis: a multireader
tricenter study. J Am Soc Nephrol, 13: 158–169
Schreiber MJ, Pohl MA and Novick AC (1984) The natural history of
atherosclerotic and fibrous renal artery disease. Urol Clin North Am, 11:
68.
69.
70.
71.
72.
73.
74.
383–392
Schreij G, de Haan MW, Oei TK, Koster D and de Leeuw PW (1999)
Interpretation of renal angiography by radiologists. J Hypertens, 17: 1737–
1741
Scoble JE (1999) Atherosclerotic nephropathy. Kidney Int Suppl, 71:
S106–9
Scoble JE (2001) Which patients benefit from angioplasty? Adv Nephrol
Necker Hosp, 31: 193–205
Simon G (2000) What is critical renal artery stenosis? Implications for
treatment. Am J Hypertens, 13: 1189–1193
Stanley JC (1997) David M. Hume memorial lecture. Surgical treatment of
renovascular hypertension. Am J Surg, 174: 102–110
Strandness DE, Jr. (1994) Duplex imaging for the detection of renal artery
stenosis. Am J Kidney Dis, 24: 674–678
Swartbol P, Thorvinger BO, Parsson H and Norgren L (1992) Renal artery
75.
76.
77.
78.
79.
stenosis in patients with peripheral vascular disease and its correlation to
hypertension. A retrospective study. Int Angiol, 11: 195–199
Tan KT, van Beek EJ, Brown PW, van Delden OM, Tijssen J and Ramsay
LE (2002) Magnetic resonance angiography for the diagnosis of renal
artery stenosis: a meta-analysis. Clin Radiol, 57: 617–624
Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D and
Zidek W (2000) Prevention of radiographic-contrast-agent-induced
reductions in renal function by acetylcysteine. N Engl J Med, 343: 180–
184
Textor SC (1998) Revascularization in atherosclerotic renal artery disease.
Kidney Int, 53: 799–811
Ubara Y, Hara S, Katori H, Yamada A and Morii H (1997) Renovascular
hypertension may cause nephrotic range proteinuria and focal
glomerulosclerosis in contralateral kidney. Clin Nephrol, 48: 220–223
van Bockel JH and Weibull H (1994) Fibrodysplastic disease of the renal
80.
81.
82.
arteries. Eur J Vasc Surg, 8: 655–657
van de Ven PJ, Kaatee R, Beutler JJ, Beek FJ, Woittiez AJ, Buskens E,
Koomans HA and Mali WP (1999) Arterial stenting and balloon
angioplasty in ostial atherosclerotic renovascular disease: a randomised
trial. Lancet, 353: 282–286
van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma
CT, Dees A, Woittiez AJ, Bartelink AK, Man in 't Veld AJ and
Schalekamp MA (2000) The effect of balloon angioplasty on hypertension
in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis
Intervention Cooperative Study Group. N Engl J Med, 342: 1007–1014
van Jaarsveld BC, Pieterman H, van Dijk LC, van Seijen AJ, Krijnen P,
Derkx FH, Man in't Veld AJ and Schalekamp MA (1999) Inter-observer
variability in the angiographic assessment of renal artery stenosis.
DRASTIC study group. Dutch Renal Artery Stenosis Intervention
Cooperative. J Hypertens, 17: 1731–1736
83.
84.
85.
86.
Veglio F, Frascisco M, Melchio R, Provera E, Rabbia F, Oliva S and
Chiandussi L (1995) Assessment of renal resistance index after captopril
test by Doppler in essential and renovascular hypertension. Kidney Int, 48:
1611–1616
Voiculescu A, Hofer M, Hetzel GR, Malms J, Modder U, Grabensee B
and Hollenbeck M (2001) Noninvasive investigation for renal artery
stenosis: contrast-enhanced magnetic resonance angiography and color
Doppler sonography as compared to digital subtraction angiography. Clin
Exp Hypertens, 23: 521–531
Watson ML, McCormick J, Thom A, Whelpdale P and Ungar A (1981)
Effects of salt and water depletion on the early phase of hypertension in
Goldblatt two-kidney hypertensive dogs. Clin Sci (Lond), 60: 625–631
Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG,
Loose H, Main J, Padfield P, Russell IT, Walker B, Watson M and
Wilkinson R (1998) Randomised comparison of percutaneous angioplasty
87.
88.
vs continued medical therapy for hypertensive patients with atheromatous
renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis
Collaborative Group. J Hum Hypertens, 12: 329–335
Weibull H, Bergqvist D, Bergentz SE, Jonsson K, Hulthen L and Manhem
P (1993) Percutaneous transluminal renal angioplasty vs. surgical
reconstruction of atherosclerotic renal artery stenosis: a prospective
randomized study. J Vasc Surg, 18: 841–850; discussion 850–852
Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar NL and
Strandness DE, Jr. (1996) A prospective study of disease progression in
patients with atherosclerotic renal artery stenosis. Am J Hypertens, 9:
1055–1061
Literatur zu Kap. 23.3
1.
Arfeen S, Rosborough D, Luger AM, Nolph KD: Familial unilateral renal
agenesis and focal and segmental glomerulosclerosis. Am J Kidney Dis
1993; 21/6: 663–668
2.
Argueso LR, Ritchey ML, Boyle ET Jr, Milliner DS, Bergstralh EJ,
Kramer SA: Prognosis of patients with unilateral renal agenesis.Pediatr
Nephrol 1992; 6/5: 412–416
3.
Ask-Upmark E: Über juvenile, maligne Nephrosklerose und ihr Verhältnis
zu Störungen in der Nierenentwicklung. Acta Pathol Microbiol Scand
1929; 6: 383
4.
Bailey RR, McRae CU, Maling TM, Tisch G, Little PJ: Renal vein renin
concentration in the hypertension of unilateral reflux nephropathy. J Urol
1978; 120/1: 21–23
5.
6.
7.
8.
9.
Bradley JE, Pincoff MC: The association of adenomyosarcoma of the
kidney (Wilm's tumour) with arterial hypertension. Ann Int Med 1938; 11:
1613
Butler AM: Chronic pyelonephritis and arterial hypertension. J Clin Invest
1937; 17: 889
el Khader K, Lrhorfi MH, el Fassi J, Tazi K, Hachimi M, Lakrissa A.:
Urogenital tuberculosis. Experience in 10 years. Prog Urol 2001 Feb;
11(1):62–67
Doray B, Gasser B, Reinartz I, Stoll C: Hereditary renal adysplasia in a
three generations family. Genet Couns 1999; 10(3): 251–7
Finelli A, Rasul I, Keystone J, Bargman JM: Development of severe
secondary hypertension in a patient with systemic entomophthoromycosis.
Am J Kidney Dis 1997 Apr; 29(4): 620–623
10.
11.
12.
13.
14.
Ganguly A, Gribbe J, Tune B, Kempson RL, Luetscher JA: Renin
secreting Wilms' tumour with severe hypertension. Annals of Internal Med
1973; 79: 835–7
Luscher TF, Vetter H, Studer A, Pouliadis G, Kuhlmann U, Glanzer K,
Largiader F, Hauri D, Greminger P, Siegenthaler W, Vetter W.: Renal
venous renin activity in various forms of curable renal hypertension. Clin
Nephrol 1981;15(6):314–320
Greenberg PB, Martin TJ, Sutcliffe HJ: Synthesis and release of
parathyroid hormone by a renal carzinoma in cell culture. Clinical science
and Molecular Medicine 1973; 45: 183–191
Haas CA, Spirnak JP: Traumatic renal artery occlusion: a review of the
literature. Tech Urol 1998; 4/1: 1–11
Hewlett JS, Hoffman GC, Senhauser DA, Battle JD: Hypernephroma with
erythrocythemia. Report of a case and assay of the tumour of an
15.
16.
17.
18.
19.
erythropoietic-stimulating substance. New Engl J Med 1956; 262: 1058–
1062
Horton BT: The relationship of hypertension to renal neoplasm.
Proceedings of the Staff Meetings of the Mayo Clinic 1940: 15: 472–474
Kaufmann JJ, Goodwin WE: Renal hypertension secondary to renal
tuberculosis. Report of cure in four patients treated by nephrectomy. Am J
Med 1965; 38: 337
Kaufman JM, Schiff M, Stansel HC: Surgical treatment of renal
hypertension in children. J Urol 1975; 113: 681–685
Kihara J, Kitamurs S, Hishimo T, Seida H, Watanabe T: A hitherto
unreported vascular tumour of the kidney. A proposal of juxtaglomerular
cell tumour. Acta Pathol Jpn 1968; 18: 197
Kincaid-Smith P: Vascular obstruction in chronic pyelonephritic kidneys
and its relation to hypertension. Lancet 1955; II: 1263
20.
21.
22.
23.
24.
Kohler J, Tencer J, Thysell H, Forsberg L: Vesicoureteral reflux diagnosed
in adulthood. Incidence of urinary tract infections, hypertension,
proteinuria, back pain and renal calculi. Nephrol Dial Transplant 1997
12/12: 2580–2587
Linder F: Hochdruck bei chirurgischen Nierenerkrankungen. Med Klinik
1948; 23: 647
Lüscher TF, Wanner C, Hauri D, Siegenthaler W, Vetter W: Curable renal
parenchymatous hypertension: current diagnosis and management.
Cardiology 1985; 72 (Suppl 1) 33–45
Marosvari J, Kontor E, Kalley K: Renin-secreting Wilm's tumour. Lancet
1972; I: 1180
Mast GJ, Isenberg E, Ziegler M: Urological diseases causing renal
hypertension. Urologe A 1981; 20/3: 123–129
25.
26.
27.
28.
29.
Mitchell JD, Baxter TJ, Blair-West JR: Renin levels in nephroblastoma
(Wilms tumor): report of a renin secreting tumour. Arch Dis Child 1970;
45: 376
Mozziaconacci P, Attal G, Boisse J, Pham-Hun-Trung MT, Guy-Grand D,
Durand C: Hypoplasie segmentaire du rein avec hypertension artérielle.
Ann Paediat 1968; 15: 337
Ohtomo Y, Matsubara T, Nishizawa K, Unno A, Motohashi T, Yamashiro
Y: Nephropathy and hypertension as manifestations in a 13-y-old girl with
primary antiphospholipid syndrome. Acta Paediatr 1998; 87/8: 903–907
Page IH: The production of persistent arterial hypertension by cellophane
perinephritis. J Am Med Assoc 1939; 113: 2046–2048
Pintar TJ, Zimmerman S: Hyperreninemic hypertension secondary to a
subcapsular perinephric hematoma in a patient with polyarteritis nodosa.
Am J Kidney Dis 1998; 32/3: 503–507
30.
31.
32.
33.
34.
35.
Robertson PW; Klidjian A, Harding LK, Walter G, Lee MR, Robb-Smith,
AHT: Hypertension due to a renin-secreting tumour. Am J Med 1967; 43:
963
Royer P, Habib R, Broyer M, Nouaille Y: Segmental hypoplasia of the
kidney in children. Adv. Nephrol 1971; 1: 145
Smith HW: Unilateral nephrectomy in hypertensive disease. J Urol 1956;
76: 685
Snodgrass WT: Hypertension associated with multicystic dysplastic
kidney in children. J Urol 2000; 164/2: 472–473; discussion 473–474
Stables DP, Fouche RF, de Villiers van Niekerk JP, Cremin BJ, Holt SA,
Peterson NE.Traumatic renal artery occlusion: 21 cases. J Urol 1976;
115/3: 229–233
Steffens J, Bock R, Braedel HU, Isenberg E, Buhrle CP, Ziegler M: Reninproducing renal cell karzinomas–clinical and experimental investigations
on a special form of renal hypertension. Urol Res 1992; 20/2) 111–115
36.
37.
38.
39.
40.
Studer UE, Weidmann P.: Pathogenesis and treatment of hypertension in
renal tuberculosis. Eur Urol 1984; 10/3: 164–169
Wesson LG: Unilateral renal disease and hypertension. Nephron 1982;
32/1: 1–7
Ziegler M, Wedel J, Ritz E: Zystische Nierenveränderungen. Aktuelle
Urologie 1974; 5: 173
Kala R, Fyhrquist F, Halttunen P, Rauste J.: Solitary renal cyst,
hypertension and renin. J Urol 1976; 116(6):710–711
Heidland A: Oxford textbook of nephrology, 2nd edn. Oxford Univ Press,
Oxford
Literatur zu Kap. 23.4
1.
Peixoto AJ, Santos SFF, Mendes RB: Reproducibility of ambulatory blood
pressure monitoring in hemodialysis patients. Am J Kidney Dis 2000; 36:
983–990
2.
Koomans HA, Braam B, Geers A B, Roos JC, Dorhout Mees EJ: The
importance of plasma protein for blood volume and blood pressure
hemostasis. Kidney Int 1986; 30: 730–735
3.
Zoccali C, Benedetto FA, Tripepi GF: Nocturnal hyoxemia, night-day
arterial pressure changes and left ventricular hypertrophy geometry in
dialysis patients. Kidney Int 1998; 53: 1078–1084
4.
Argiles A, Mourad G, Mion C: Seasonal changes in blood pressure in
patients with end-stage renal disease treated with hemodialysis. N Engl J
Med 1998; 339: 1364–1370
5.
6.
7.
8.
9.
Ritz E, Koomans HA: New insights into mechanisms of blood pressure
regulation in patients with uremia. Nephrol Dial Transplant 1996; 11
(Suppl. 2): 62–66
Guyton AC, Granger HJ, Coleman TG: Autoregulation of the total
systemic circulation and its relation to control of cardiac output and
arterial pressure. Circ Res 1971; 28 (Suppl 1): 93–97
Luik A J, van Kuijk WH, Spek J: Effects of hypervolemia in interdialytic
hemodynamics and blood pressure control in hemodialysis patients. Am J
Kidney Dis 1997; 30: 466–474
Chazot C, Charra B, Vovan C: The Janus faced aspect of dry weight.
Nephrol Dial Transplant 1999; 14: 121–124
Weidmann P: Pathogenesis of hypertension associated with chronic renal
failure. Contrib Nephrol 1984; 411: 47–65
10.
11.
12.
13.
14.
Kucera M, Hilgers KF, Lisson C: Local angiotensin formation in
hindlimbs of uremic hypertensive and renovascular hypertensive rats. J
Hypertens 1991; 9: 41–48
Ligtenberg G, Blankenstijn PJ, Oey PL: Reduction of sympathetic activity
by enalapril in patients with chronic renal failure. N Engl J Med 1999;
340: 1321–1328
Kielstein JT, Böger RH, Bode-Böger SM: Asymmetric dimethy arginine
plasma concentrations differ in patients with end-stage renal disease:
relationship to treatment method and atheroslerotic disease. Am Soc
Nephrol 1999; 10: 594–600
Amann K, Gross ML, London GM, Ritz E: Hyperphosphataemia- a silent
killer of patients with renal failure? Nephrol Dial Transplant 1999; 14:
2085–2087
London GM: Arterial function in renal failure. Nephrol Dial Transplant
1998; 13 (Suppl 4): 12–15
15.
16.
17.
18.
19.
London GM, Guerin AP, Pannier B, Marchais S, Benetos A, Safar M:
Increased systolic pressure in chronic uremia: role of arterial wave
reflections Hypertension 1992; 20: 10–19
Scribner BH, Buri R, Caner JE, Hegstrom R, Burnell JM: The treatment of
chronic uremia by means of intermittend hemodialysis: a preliminary
report. 1960; J Am Soc Nephrol 1998, 9: 719–726
Doorhout-Mees EJ: Volemia and blood pressure in renal failure: have old
truth been forgotten. Nephrol Dial Transplant 1995; 10: 1297–1298
Koomans HA, Roos J C, Dorhout Mees EJ: Sodium balance in renal
failure. A comparison of patients with normal subjects under extremes of
sodium intake. Hypertension 1985; 7: 714–721
Shemin D, Dworkin LD: Sodium balance in renal failure. Curr Opin
Nephrol Hypertens 1997; 6: 128–132
20.
21.
22.
23.
24.
Özkahya M, Toz H, Unsal A: Treatment of hypertension in dialysis
patients by ultrafiltration: role of cardiac dilatation and time factor. Am J
Kidney Dis 1999; 34: 218–221
Thomson GE, Waterhouse K, McDonald HP Jr, Friedman EA:
Hemodialysis for chronic renal failure. Clinical observations. Arch Int
Med 1967; 120: 153–167
Charra B, Calemard E, Ruffet M: Survival as an index of adequacy of
dialysis. Kidney Int 1992; 41: 1286–1291
Innes A, Charra B, Burden RP, Morgan AG, Laurent G: The effect of long,
slow haemodialysis on patient survival. Nephrol Dial Transplant 1999; 14:
919–922
Kooistra MP, Vos J, Koomans HA, Vos PF: Daily home hemodialysis in
The Netherlands: effects on metabolic control, hemodynamics, and quality
of life. Nephrol Dial Transplant 1998; 13: 2853–2860
25.
26.
27.
28.
29.
MacGregor DO, Buttimore AL, Nicholls MG, Lynn KL: Ambulatory
blood pressure monitoring in patients receiving long, slow home
hemodialysis. Nephrol Dial Transplant 1999; 14: 2676–2679
Port FK, Hulbert-Sheron TE, Wolfe RA, Bloembergen WE: Predialysis
blood pressure and mortality risk in a national sample of maintenance
hemodialysis patients. Am J Kidney Dis 1999; 33: 507–517
Zager PG, Nikolic J, Bown RH, Campbell MA, Hunt WC: "U" curve
association of blood pressure and mortality in hemodialysis patients.
Kidney Int 1998; 54: 561–569
Glynn R J; Field TS, Rosner B, Hebert PR, Taylor JO: Evidence for a
positive linear relation between blood pressure and mortality in elderly
people. Lancet 1995; 345: 825–829
Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM:
Impact of aortic stiffness on survival in end-stage renal disease.
Circulation 1999; 99: 2432–2439
30.
31.
32.
33.
34.
London GM: The concept of ventricular vascular coupling: functional and
structural alterations of the heart and the arterial vessels go in parallel.
Nephrol Dial Transplant1998; 13: 250–253
Cirit M, Akcicek F, Terzioglu E, Soydas C, Ok E, Ozbasli CF, Basci A,
Mees EJ: Paradoxical rise in blood pressure during ultrafiltration. Nephrol
Dial Transplant 1995; 10: 1417–1420
Charra B, Bergstrom J, Scribner BH: Blood pressure in dialysis patients:
importance of the lag phenomenon. Am J Kidney Dis 1998; 32: 720–724
Converse RL, Jakobson TN, Toto RD, Jost CMT, Cosentino F, FouadTarazi F, Victor RG: Sympathetic overactivity in patients with CRF. N
Engl J Med 1992; 327: 1912–1918
Zuanetti G, Maggioni AP, Keane W, Ritz E: Nephrologists neglect
administration of beta blockers in dialysed diabetic patients. Nephrol Dial
Transplant 1997; 12: 2497–2500
35.
Agarwal R: Supervised atenolol therapy in the management of
hemodialysis hypertension. Kidney Int 1999; 55: 1528–1535
Literatur zu Kap. 23.5
1.
Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ,
Stablein D (2000) Improved graft survival after renal transplantation in the
United States, 1988 to 1996. N Engl J Med 342: 605–612
2.
Schomig M, Schwenger V, Ritz E (2000) Circadian rhythm of blood
pressure in renal disease. Curr Hypertens Rep 2: 490–494
3.
Frei U, Schindler R, Wieters D, Grouven U, Brunkhorst R, Koch KM
(1995) Pre-transplant hypertension- a major risk factor for chronic
progressive renal allograft dysfunction ? Nephrol Dial Transplant. 10:
1206–1211
4.
Opelz G, Wujciak T, Ritz E (1998) Association of chronic kidney graft
failure with recipient blood pressure. Kidney Int 53: 217–222
5.
Foley RN, Parfrey PS, Harnett JD et al. (1995) Clinical and
echocardiographic disease in patients starting end-stage renal disease
therapy. Kidney-Int 47: 186–192
6.
7.
8.
9.
10.
11.
USRDS (1997) Incidence and prevalence of ESRD. USRDS. United States
Renal Data System. Am J Kidney Dis 30: S40–53
Hannedouche T, Chauveau P, Kalou F, Albouze G, Lacour B, Jungers P
(1993) Factors affecting progression in advanced chronic renal failure.
Clin Nephrol 39: 312–320
Stefanski A, Schmidt KG, Waldherr R, Ritz E (1996) Early increase in
blood pressure and diastolic left ventricular malfunction in patients with
glomerulonephritis. Kidney-Int 50: 1321–1326
Fricke L, Doehn C, Steinhoff J, Sack K, Jocham D, Fornara P (1998)
Treatment of posttransplant hypertension by laparoscopic bilateral
nephrectomy? Transplantation 65: 1182–1187
Briggs JD, Jones E (1999) Recurrence of glomerulonephritis following
renal transplantation. Nephrol Dial Transplant 14: 564–565
Hariharan S (2000) Recurrent and de novo diseases after renal
transplantation. Semin Dial 13: 195–199
12.
13.
14.
15.
16.
Ohmacht C, Kliem V, Burg M et al. (1997) Recurrent immunoglobulin A
nephropathy after renal transplantation: a significant contributor to graft
loss. Transplantation 64: 1493–1496
Curtis JJ (1998) Posttransplant hypertension. Transplant Proc 30: 2009–
2011
Norling LL, Tufro McReddie A, Ariel Gomez R, Moore LC, Kaskel FJ
(1996) Accumulation of acidic renin isoforms in kidneys of cyclosporineA-treated rats. J Am Soc Nephrol 7: 331–337
Haas M, Mayer G (1997) Cyclosporin A-associated hypertension–
pathomechanisms and clinical consequences [editorial]. Nephrol DialTransplant 12: 395–398
Mayer AD, Dmitrewski J, Squifflet JP et al. (1997) Multicenter
randomized trial comparing tacrolimus (FK506) and cyclosporine in the
prevention of renal allograft rejection: a report of the European Tacrolimus
Multicenter Renal Study Group. Transplantation 64: 436–443
17.
18.
19.
20.
European FK506 Multicentre Liver Study Group (1994) Randomised trial
comparing tacrolimus (FK506) and cyclosporin in prevention of liver
allograft rejection. Lancet 344: 423–428
The U.S. multicenter FK506 liver study group (1994) A comparison of
tacrolimus (FK506) and cyclosporine for immunosuppression in liver
transplantation. N Engl J Med 331: 1110–1115
Taylor DO, Barr ML, Radovancevic B et al. (1999) A randomized,
multicenter comparison of tacrolimus and cyclosporine
immunosuppressive regimens in cardiac transplantation: decreased
hyperlipidemia and hypertension with tacrolimus. J-Heart-LungTransplant 18: 336–345
Reyes J, Jain A, Mazariegos G et al. (2000) Long-term results after
conversion from cyclosporine to tacrolimus in pediatric liver
transplantation for acute and chronic rejection. Transplantation 69: 2573–
2580
21.
22.
23.
24.
25.
Ligtenberg G, Hene R, Blankestijn P, Koomans H (2001) Cardiovascular
risk factors in renal transplant patients: cyclosporin a vs. tacrolimus. J Am
Soc Nephrol 12: 368–73
Whitworth JA, Brown MA, Kelly JJ, Williamson PM (1995) Experimental
studies on cortisol-induced hypertension in humans. J Hum Hypertens 9:
395–399
Cosio FG, Pelletier RP, Sedmak DD, Pesavento TE, Henry ML, Ferguson
RM (1999) Renal allograft survival following acute rejection correlates
with blood pressure levels and histopathology. Kidney Int 56: 1912–1219
Mange KC, Cizman B, Joffe M, Feldman HI (2000) Arterial hypertension
and renal allograft survival. JAMA 283: 633–638
Nakano S, Ogihara M, Tamura C et al. (1999) Reversed circadian blood
pressure rhythm independently predicts endstage renal failure in noninsulin-dependent diabetes mellitus subjects. J Diabetes Complicat 13:
224–231
26.
27.
28.
29.
30.
Curtis JJ, Luke RG, Jones P, Diethelm AG (1988) Hypertension in
cyclosporine-treated renal transplant recipients is sodium dependent [see
comments]. Am J Med 85: 134–138
Groth CG, Backman L, Morales JM et al. (1999) Sirolimus (rapamycin)based therapy in human renal transplantation: similar efficacy and
different toxicity compared with cyclosporine. Sirolimus European Renal
Transplant Study Group [see comments]. Transplantation 67: 1036–1042
McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald
AS (2000) Sirolimus-tacrolimus combination immunosuppression [letter].
Lancet 355: 376–377
Hueso M, Bover J, Seron D et al. (1998) Low-dose cyclosporine and
mycophenolate mofetil in renal allograft recipients with suboptimal renal
function. Transplantation 66: 1727–1731
Schrama YC, Joles JA, van Tol A, Boer P, Koomans HA, Hene RJ (2000)
Conversion to mycophenolate mofetil in conjunction with stepwise
31.
32.
33.
34.
withdrawal of cyclosporine in stable renal transplant recipients.
Transplantation 69: 376–383
Szabo A, Lutz J, Schleimer K et al. (2000) Effect of angiotensinconverting enzyme inhibition on growth factor mRNA. Kidney Int 57:
982–991
Ziai F, Nagano H, Kusaka M et al. (2000) Renal allograft protection with
losartan in fisher–>Lewis rats. Kidney Int 57: 2618–2625
Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi
G (1998) Chronic allograft nephropathy in the rat is improved by
angiotensin II receptor blockade but not by calcium channel antagonism. J
Am Soc Nephrol 9: 1948–1955
Suwelack B, Gerhardt U, Hausberg M, Rahn KH, Hohage H (2000)
Comparison of quinapril vs. atenolol: effects on blood pressure and. Am J
Cardiol 86: 583–585, A10
35.
Zazgornik J, Biesenbach G, Janko O et al. (1998) Bilateral nephrectomy:
the best, but often overlooked, treatment for refractory hypertension in
hemodialysis patients. Am J Hypertens 11: 1364–1370
Literatur zu Kap. 23.6
1.
Weitz W (1922) Zur Ätiologie der genuinen oder vaskuären Hypertension.
Z Klin Med 96: 151–173
2.
Lifton RP (1996) Molecular genetics of human blood pressure variation.
Science 272: 676–680
3.
Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke
G, Tsai FT, Sigler PB, Lifton RP (2000) Activating mineralocorticoid
receptor mutation in hypertension exacerbated by pregnancy. Science.
289: 119–123
4.
Mansfield TA, Simon DB, Farfel Z et al. (1997) Multilocus linkage of
familial hyperkalaemia and hypertension, pseudohypoaldosteronism type
II, to chromosomes 1q31–42 and 17p11-q21. Nat Genet 16: 202–205
5.
Schuster H, Wienker TF, Bähring S et al. (1996) Severe autosomal
dominant hypertension and brachydactyly in a unique Turkish kindred
maps to human chromosome 12. Nat Genet 4: 98–100
6.
7.
8.
9.
10.
11.
12.
Luft FC (1999) Molecular genetics of hypertension. Curr Opin Nephrol
Hypertensiol
Kunz R, Kreutz R, Beige J, Distler A, Sharma AM (1997) Association
between the angiotensinogen 235T-variant and essential hypertension in
whites: a systematic review and methodological appraisal. Hypertension
30: 1331–1337
Manunta P, Cusi D, Barlassina C et al. (1998) -Adducin polymorphisms
and renal sodium handling in essential hypertensive patients. Kidney Int
53: 1471–11478
Siffert W, Rosskopf D, Siffert G et al. (1998) Association of a human Gprotein beta3 subunit variant with hypertension. Nat Genet 18: 8–10
Iwai N, Katsuya T, Ishikawa K et al. (1999) Human prostacyclin synthase
gene and hypertension: The Suita Study. Circulation 100: 2231–2236
Luft FC, Busjahn A (2001) Peaks and valleys. Hypertension (in press)
Horikawa Y, Oda N, Cox NJ et al. (2000) Genetic variation in the gene
13.
14.
15.
16.
17.
encoding calpain–10 is associated with type 2 diabetes mellitus. Nat
Genet. 26: 163–175
Pickering G (1961) The nature of hypertension. Churchill, London
Guidelines subcommittee (1998) 1999 World Health Organization –
International Society of Hypertension guidelines for the management of
hypertension. J Hypertens 17: 151–183
Fulker DW, Cherny SS, Sham PC, Hewitt JK (1999) Combined linkage
and association sib-pair analysis for quantitative traits. Am J Hum Genet
64: 259–267
Nagy Z, Busjahn A, Bhring S et al. (1999) Quantitative trait loci for blood
pressure exist near the IGF–1, the Liddle syndrome, and the angiotensin IIreceptor gene loci in man. J Am Soc Nephrol 10: 1709–1716
Busjahn A, Li G-H, Faulhaber H-D et al. (2000) α–2 adrenergic receptor
gene variations, heart size, and blood pressure in normal twins.
Hypertension 35: 555–560
Literatur zu Kap. 23.7
1.
Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S (1996) Calcium
channel blockers vs. other antihypertensive therapies on progression of
NIDDM associated nephropathy. Kidney Int 50: 1641–1650
2.
Bakris GL, Weir MR, DeQuattro V, McMahon FG (1998) Effects of an
ACE inhibitor/calcium antagonist combination on proteinuria in diabetic
nephropathy. Kidney Int 54: 1283–1289
3.
Blüthner M, Schmidt S, Siffert W, Knigge H, Nawroth P, Ritz E (1999)
Increased frequency of G-protein beta 3-subunit 825 T allele in dialyzed
patients with type 2 diabetes. Kidney Int 55: 1247–1250
4.
Bowden DW, Sale M, Howard TD et al. (1997) Linkage of genetic
markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib
pairs with a history of diabetic nephropathy. Diabetes 46: 882–886
5.
6.
7.
8.
9.
Christensen PK, Hansen HP, Parving HH (1997) Impaired autoregulation
of GFR in hypertensive non-insulin dependent diabetic patients. Kidney
Int 52: 1369–1374
Cooper ME (1998) Pathogenesis, prevention, and treatment of diabetic
nephropathy. Lancet 352: 213–219
Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM
(1989) Disparities in incidence of diabetic end-stage renal disease
according to race and type of diabetes. N Engl J Med 321: 1074–1079
Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier
RW (1998) The effect of nisoldipine as compared with enalapril on
cardiovascular outcomes in patients with non-insulin-dependent diabetes
and hypertension. N Engl J Med 338: 645–652
Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT (1982) The kidney in
maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney
Int 21: 730–738
10.
11.
12.
13.
Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H
(1997) Insulin resistance, hyperinsulinemia, and blood pressure: role of
age and obesity. European Group for the Study of Insulin Resistance
(EGIR). Hypertension 30: 1144–1149
Fliser D, Schröter M, Neubeck M, Ritz E (1994) Coadministration of
thiazides increases the efficacy of loop diuretics even in patients with
advanced renal failure. Kidney Int 46: 482–488
Forsblom C, Trenkwalder P, Dahl K, Mulder H (1997) Candesartan
cilexetil, a novel angiotensin II antagonist reduces microalbuminuria in
patients with type II diabetes mellitus and mild hypertension. J Hypertens
15 Suppl 4: 113
Gall MA, Rossing P, Skott P et al. (1991) Prevalence of micro- and
macroalbuminuria, arterial hypertension, retinopathy and large vessel
disease in European type 2 (non-insulin-dependent) diabetic patients.
Diabetologia 34: 655–661
14.
15.
16.
17.
Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL (2000)
Hypertension and antihypertensive therapy as risk factors for type 2
diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J
Med 342: 905–912
Guasch A, Parham M, Zayas CF, Campbell O, Nzerue C, Macon E (1997)
Contrasting effects of calcium channel blockade vs. converting enzyme
inhibition on proteinuria in African Americans with non-insulin-dependent
diabetes mellitus and nephropathy. J Am Soc Nephrol 8: 793–798
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998)
Mortality from coronary heart disease in subjects with type 2 diabetes and
in nondiabetic subjects with and without prior myocardial infarction. N
Engl J Med 339: 229–234
Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive
blood-pressure lowering and low-dose aspirin in patients with
18.
19.
20.
21.
hypertension: principal results of the Hypertension Optimal Treatment
(HOT) randomised trial. HOT Study Group. Lancet 351: 1755–1762
Hasslacher C, Ritz E, Wahl P, Michael C (1989) Similar risks of
nephropathy in patients with type I or type II diabetes mellitus. Nephrol
Dial Transplant 4: 859–863
Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects
of ramipril on cardiovascular and microvascular outcomes in people with
diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.
Lancet 355: 253–259
Huston P, Peterson R (2001) Withholding proven treatment in clinical
research. N Engl J Med 345: 912–914
Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC
(1998) Sib-pair linkage analysis for susceptibility genes for microvascular
complications among Pima Indians with type 2 diabetes. Pima Diabetes
Genes Group. Diabetes 47: 821–830
22.
23.
24.
25.
26.
Ismail N, Becker B, Strzelczyk P, Ritz E (1999) Renal disease and
hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 55: 1–
28
Jacobson HR, Striker GE (1995) Report on a workshop to develop
management recommendations for the prevention of progression in
chronic renal disease. Am J Kidney Dis 25: 103–106
Jeffers BW, Estacio RO, Raynolds MV, Schrier RW (1997) Angiotensinconverting enzyme gene polymorphism in non-insulin dependent diabetes
mellitus and its relationship with diabetic nephropathy. Kidney Int 52:
473–477
Joint National Committee VI (1997) The sixth report of the Joint National
Committee on prevention, detection, evaluation, and treatment of high
blood pressure. Arch Intern Med 157: 2413–2446
Keller CK, Bergis KH, Fliser D, Ritz E (1996) Renal findings in patients
with short-term type 2 diabetes. J Am Soc Nephrol 7: 2627–2635
27.
28.
29.
30.
31.
Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF (1998) Antihypertensive
treatment of patients with proteinuric renal diseases: risks or benefits of
calcium channel blockers? Kidney Int 53: 1559–1573
Koomans HA, Roos JC, Dorhout Mees EJ, Delawi IM (1985) Sodium
balance in renal failure. A comparison of patients with normal subjects
under extremes of sodium intake. Hypertension 7: 714–721
Koren W, Koldanov R, Pronin VS et al. (1997) Amiloride-sensitive
Na+/H+ exchange in erythrocytes of patients with NIDDM: a prospective
study. Diabetologia 40: 302–306
Krolewski AS (1999) Genetics of diabetic nephropathy: evidence for
major and minor gene effects. Kidney Int 55: 1582–1596
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of
angiotensin-converting-enzyme inhibition on diabetic nephropathy. The
Collaborative Study Group. N Engl J Med 329: 1456–1462
32.
33.
34.
35.
36.
Lewis EJ, Hunsicker LG, Clarke WR et al. (2001) Renoprotective effect of
the angiotensin-receptor antagonist irbesartan in patients with nephropathy
due to type 2 diabetes. N Engl J Med 345: 851–860
Maschio G, Alberti D, Janin G et al. (1996) Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal
insufficiency. The Angiotensin-Converting-Enzyme Inhibition in
Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939–945
Mogensen CE (1998) Combined high blood pressure and glucose in type 2
diabetes: double jeopardy. British trial shows clear effects of treatment,
especially blood pressure reduction. BMJ 317: 693–694
Mogensen CE (1999) Microalbuminuria, blood pressure and diabetic renal
disease: origin and development of ideas. Diabetologia 42: 263–285
Mogensen CE, Keane WF, Bennett PH et al. (1995) Prevention of diabetic
renal disease with special reference to microalbuminuria. Lancet 346:
1080–1084
37.
38.
39.
40.
Nakano S, Fukuda M, Hotta F et al. (1998) Reversed circadian blood
pressure rhythm is associated with occurrences of both fatal and nonfatal
vascular events in NIDDM subjects. Diabetes 47: 1501–1506
Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH (1997)
Long-term effect of lisinopril and atenolol on kidney function in
hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:
1182–1188
Olivarius Nde F, Andreasen AH, Keiding N, Mogensen CE (1993)
Epidemiology of renal involvement in newly-diagnosed middle-aged and
elderly diabetic patients. Cross-sectional data from the population-based
study "Diabetes Care in General Practice", Denmark. Diabetologia 36:
1007–1016
Orth SR, Amann K, Strojek K, Ritz E (2001) Sympathetic overactivity and
arterial hypertension in renal failure. Nephrol Dial Transplant 16 Suppl 1:
67–69
41.
42.
43.
44.
45.
46.
Orth SR, Ritz E (1998) The nephrotic syndrome. N Engl J Med 338:
1202–1211
Orth SR, Ritz E (2001) Specific organ protection by blocking the reninangiotensin system. Nephrol Dial Transplant 16 Suppl 6: 40–42
Orth SR, Ritz E: Einsatz von Kalziumkanalblockern zur Nephroprotektion.
In: Bönner G, Dominiak P (Hrsg.) Kalziumantagonisten-Handbuch.
Stuttgart: Schattauer-Verlag, 2002; 391–416
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S,
Arner P (2001) The effect of irbesartan on the development of diabetic
nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870–878
Peterson JC, Adler S, Burkart JM et al. (1995) Blood pressure control,
proteinuria, and the progression of renal disease. The Modification of Diet
in Renal Disease Study. Ann Intern Med 123: 754–762
Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC (1990)
Familial predisposition to renal disease in two generations of Pima Indians
47.
48.
49.
50.
with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33:
438–443
Pittrow DB, Antlsperger A, Welzel D, Wambach G, Schardt W,
Weidinger G (1997) Evaluation of the efficacy and tolerability of a lowdose combination of isradipine and spirapril in the first-line treatment of
mild to moderate essential hypertension. Cardiovasc Drugs Ther 11: 619–
627
Price DA, Porter LE, Gordon M et al. (1999) The paradox of the low-renin
state in diabetic nephropathy. J Am Soc Nephrol 10: 2382–2391
Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R (1998) Main
risk factors for nephropathy in type 2 diabetes mellitus are plasma
cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern
Med 158: 998–1004
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M (1993) Long-term
stabilizing effect of angiotensin-converting enzyme inhibition on plasma
51.
52.
53.
54.
55.
creatinine and on proteinuria in normotensive type II diabetic patients.
Ann Intern Med 118: 577–581
Remuzzi G, Bertani T (1998) Pathophysiology of progressive
nephropathies. N Engl J Med 339: 1448–1456
Ritz E, Lippert J, Keller C (1996) Rapider Anstieg der Zahl
niereninsuffizienter Typ-II-Diabetiker. Dtsch Med Wochenschr 121: 1247
Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes
mellitus. N Engl J Med 341: 1127–1133
Ritz E, Rychlik I, Locatelli F, Halimi S (1999) End-stage renal failure in
type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J
Kidney Dis 34: 795–808
Ritz E, Stefanski A (1996) Diabetic nephropathy in type II diabetes. Am J
Kidney Dis 27: 167–194
56.
57.
58.
59.
60.
Rump LC, Amann K, Orth S, Ritz E (2000) Sympathetic overactivity in
renal disease: a window to understand progression and cardiovascular
complications of uraemia? Nephrol Dial Transplant 15: 1735–1738
Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of aggressive
blood pressure control in normotensive type 2 diabetic patients on
albuminuria, retinopathy and strokes. Kidney Int 61: 1086–1097
Sica DA, Douglas JG (2001) The African American Study of Kidney
Disease and Hypertension (AASK): new findings. J Clin Hypertens
(Greenwich) 3: 244–251
Stefanski A, Amann K, Ritz E (1995) To prevent progression: ACE
inhibitors, calcium antagonists or both? Nephrol Dial Transplant 10: 151–
153
Strojek K, Grzeszczak W, Morawin E et al. (1997) Nephropathy of type II
diabetes: evidence for hereditary factors? Kidney Int 51: 1602–1607
61.
62.
63.
64.
65.
Tarnow L, Gluud C, Parving HH (1998) Diabetic nephropathy and the
insertion/deletion polymorphism of the angiotensin-converting enzyme
gene. Nephrol Dial Transplant 13: 1125–1130
The EUCLID Study Group (1997) Randomised placebo-controlled trial of
lisinopril in normotensive patients with insulin-dependent diabetes and
normoalbuminuria or microalbuminuria. Lancet 349: 1787–1792
The GISEN Group (1997) Randomised placebo-controlled trial of effect of
ramipril on decline in glomerular filtration rate and risk of terminal renal
failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857–1863
Trenkwalder P, Dahl K, Lehtovirta M, Mulder H (1998) Antihypertensive
treatment with candesartan cilexetil does not affect glucose homeostasis or
serum lipid profile in patients with mild hypertension and type II diabetes.
Blood Press 7: 170–175
Tuomilehto J, Rastenyte D, Birkenhager WH et al. (1999) Effects of
calcium-channel blockade in older patients with diabetes and systolic
66.
67.
68.
69.
hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl
J Med 340: 677–684
U.S. Renal Data System (1998) USRDS 1998 Annual Report. National
Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases Bethesda, MD, April 1998
UK Prospective Diabetes Study Group (1998) Tight blood pressure control
and risk of macrovascular and microvascular complications in type 2
diabetes: UKPDS 38. BMJ 317: 703–713
Velussi M, Brocco E, Frigato F et al. (1996) Effects of cilazapril and
amlodipine on kidney function in hypertensive NIDDM patients. Diabetes
45: 216–222
Viberti G, Mogensen CE, Groop LC, Pauls JF (1994) Effect of captopril
on progression to clinical proteinuria in patients with insulin-dependent
diabetes mellitus and microalbuminuria. European Microalbuminuria
Captopril Study Group. JAMA 271: 275–279
70.
71.
72.
73.
Wagner J, Gehlen F, Ciechanowicz A, Ritz E (1999) Angiotensin II
receptor type 1 gene expression in human glomerulonephritis and diabetes
mellitus. J Am Soc Nephrol 10: 545–551
Weidmann P, Boehlen LM, de Courten M (1993) Effects of different
antihypertensive drugs on human diabetic proteinuria. Nephrol Dial
Transplant 8: 582–584
World Health Organization-International Society of Hypertension (1999)
1999 World Health Organization-International Society of Hypertension
Guidelines for the Management of Hypertension. Guidelines
Subcommittee. J Hypertens 17: 151–183
Yokoyama H, Tomonaga O, Hirayama M et al. (1997) Predictors of the
progression of diabetic nephropathy and the beneficial effect of
angiotensin-converting enzyme inhibitors in NIDDM patients.
Diabetologia 40: 405–411
Literatur zu Kap. 23.8
1.
Andersen GS, Toftdahl DB, Lund JO, Strandgaard S, Nielsen PE (1988)
The incidence rate of pheochromocytoma and Conn's syndrome in
Denmark, 1977–1988. J Hum Hypertens 2: 187–189
2.
Anderson DJ (1993) Molecular control of cell fate in the neutral crest –
The sympathoadrenal lineage. Annu Rev Neurosci 16: 129–158
3.
Aprill BS, Drake AJ III, Lasseter DH, Shakir KM (1994) Silent adrenal
nodules in von Hippel-Lindau disease suggest pheochromocytoma. Ann
Intern Med 120: 485–487
4.
Baysal BE, Ferrel RE, Willett-Brozick JE et al. (2000) Mutations in
SDHC, a mitochondrial complex II gene, in hereditary paraganglioma.
Sciene 98: 32–36
5.
Bergland BE (1989) Pheochromocytoma presenting as shock. Am J Emerg
Med 7: 44–48
6.
7.
8.
9.
10.
Bouloux P, Fakeeh M (1995) Investigation of pheochromocytoma. Clin
Endocrinol 43: 657–664
Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford Jr RW (1981)
Clonidine-suppression: a useful aid in the diagnosis of
pheochromozytoma. N Engl J Med 305: 623–626
Bravo EL (1994) Evolving concept in the pathophysiology, dieagnosis,
and treatment of pheochromocytoma. Endocr Rev 15: 356–368
Brown HM, Komorowski RA, Wilson SD, Demeure MJ, Zhu YR (1999)
Predicting metastasis of pheochromocytomas using DNA flow cytometry
and immunhistochemical merkers of cell proliferation – A positive
correlation between MIB–1 staining and malignant tumor behavior.
Cancer 86: 1583–1589
Bullough A, Karadia S, Watters M (2001) Pheochromocytoma: an unusual
cause of hypertension in pregnancy. Anaesthesia 56: 43–46
11.
12.
13.
14.
15.
16.
Cohen CD, Dent DM (1984) Pheochromocytoma and acute cardiovascular
death (with special reference to myocardial infarction). Postgrad Med J 60:
111–115
Dean RE (1958) Pheochromocytoma and pregnancy. Obstet Gynecol 11:
35–42
Deimling von A, Krone W, Menon AG (1995) Neurofibromatosis type 1:
pathology, clinical freatures, and molecular genetics. Brain Pathol 5: 173–
180
Desmonts JM, Marty J (1984) An anesthetic management of patients with
pheochromocytoma. Br J Anesth 56: 781–789
Doppman JL, Reinig JW, Dwyer AJ et al. (1987) Differentiation of
adrenal masses by magnetic resonance imaging. Surgery 102: 1018–1026
Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS,
Keiser HR (1999) Plasma normetanephrine and metanephrine for detecting
17.
18.
19.
20.
21.
pheochromocytoma in von Hippel-Lindau disease and multiple endocrine
neoplasia type 2. N Engl. J Med 340: 1872–1879
El-Minawi MF, Paulino E, Cuesta M, Ceballos J (1971)
Pheochromocytoma masquerading as pre-eclamptic toxemia. Am J Obstet
Gynecol 109: 389–395
Elliot WJ, Murphy MB, Straus FH, Jarabak J (1989) Improved safety of
glugacon testing for pheochromocytoma by prior alpha-receptor blockade.
Arch Intern Med 149: 214–216
Eng C (1996) Seminars in medicine of Beth Israel Hospital, Boston. The
RET proto-oncogene in multiple endocrine neolasia type 2 and
Hirschsprung's disease. N Engl J Med 335: 943–951
Fernandez-Calvet L, Garcia-Mayor RV (1994) Incidence of
pheochromocytoma in South Galicia, Spain. J Intern Med 236: 675–677
Francis IR, Gross MD, Shapiro B, Korobkin M, Quint LE (1992)
Integrated imaging of adrenal disease. Radiology 184: 1–13
22.
23.
24.
25.
26.
27.
Fries JG, Chamberlin JA (1968) Extra-adrenal pheochromocytoma:
Literature review and report of a cervikal pheochromocytoma. Surgery 63:
268–279
Gabita-Rosei E, Alicandri CI, Corea I (1977) Hypertensive crises in
patients with pheochromozytoma given metoclopramide. Lancet 1: 600
Gill PS (2000) Acute heart failure in the parturient – do not forget
pheochromocytoma. Anaesth Intensiv Care 28: 322–324
van Gils APG, Falke THM, van Erkel AR et al. (1991) MR imaging and
MIBG scintigraphy of pheochromocytomas and extraadrenal functioning
paragangliomas. Radiograph 11: 37–57
Gimm O, Armanios M, Dziema H, Neumann HPH, Eng C (2000) Somatic
and occult germline mutations in SDHD, a mitochondrial complex II gene,
in non-familial pheochromocytomas. Cancer Res 60: 6822–6825
Glazer GM, Francis IR, Quint LE (1988) Imaging of the adrenal glands.
Invest Radiol 23: 3–11
28.
29.
30.
31.
32.
33.
Graham JB (1951) Pheochromocytoma and hypertension. An analysis of
207 cases. Int Abstr. Surg 92: 105–121
Griffith MI, Felts JH, James FM, Meyers RT, Shealy GM, Woodruff LF jr
1974 Successful control of pheochromocytoma in pregnancy
Grossmann E, Goldstein DA, Hoffman A, Keiser HR (1991) Glucagon
and clonidine testing in the diagnosis of pheochromocytoma. Hypertension
17: 733–741
Hadden DR (1995) Adrenal disorders of pregnancy. Endocr Metab Clin N
Am 24: 139
Harrison TS, Freier DT 1974 Pitfalls in the technique and interpretation of
regional venous sampling for localizing pheochromocytoma. Surg Clin
North Am 54: 339–347
Helle KB, (1990) Chromogranins: Universal proteins in secretory granules
from paramecium to man. Neurochem Int 17: 165
34.
35.
36.
37.
38.
Hifford RW Jr, Kvale WF, Maher FT, Roth GM, Priestly JT (1964)
Clinical features, diagnosis and treatment of pheochromocytoma. Surgery
63: 268–279
Hsiae RJ, Neumann HP, Parmer RL, Barbosa JA, O'Connor DT (1990)
Chromogranin A in familial pheochromocytoma: diagnostic screening
value, prediction of tumor mass, and post-secretion kinetics indicating two
compartment distribution. Am J Med 88: 607–613
Hoefnagel CA, Voute PA, de Kraker J, Marcuse HR (1987) Radionuclide
diagnosis and therapie of neural crest tumors usong iodine–131metaiodobenzylguanidine. J Nucl Med 28: 308–314
Hull CJ (1986) Pheochromocytoma. Diagnosis, preoperative preparation
and anesthetic management. Br J Anaesth 58: 1453
Hume DM (1960) Pheochromocytoma in the adult and in the child. Am J
Surg 99: 458–496
39.
40.
41.
42.
43.
44.
Huston JR, Stewart WRC (1965) Hemorrhagic pheochromocytoma with
shock and abdominal pain. Am J Med 39: 502–504
Khafagi FA, Shapiro B, Fig LM, Malette S, Sisson JC (1989) Labetalol
reduces iodine–131-MIBG uptake by pheochromocytoma and normal
tissues. J Nucl Med 30: 481
Kloos RT, Gross MD, Francis IE, Korobkin M, Shapiro B (1995)
Incidentally discovered adrenal masses. Endcrine Rev 16: 460–484
Krane NK (1986) Clinically unsuspected pheochromcytoma: experience at
Henry Ford Hospital and a review of the literature. Arch Intern Med 146:
54–57
Kuchel O (1998) Increased plasma dopamine in patients presenting withe
the pseudopheochromocytoma
Lack EE, (1997) Tumors of the adrenal gland and extra-adrenal
paraganglia, Atlas ot tumor pathology, 3 rd series, fascie 19. Armed
Forces Institute of Pathology, Washington DC, pp 1–468
45.
46.
47.
48.
49.
50.
Lamberts SWL, Bakker WH, Reubi JC (1990) Somatostatin-receptor
imaging in the localization of endocrine tumors. N Engl J Med 323: 1246–
1249
Latif F, Tory K, Gnarra J et al. (1993) Identification of the von HippelLindau disease tumor suppressor gene. Sciene 260: 1317–1320
Lehnert H (1998) Phäochromozytom. In: Domschke W, Hohenberger W,
Meinertz T, Possinger K, Reinhardt D, Dölle R (Hrsg) Therapiehandbuch.
Urban & Schwarzenberg, München, K8 1–8
Lehnert H (1996) Regulation of catecholamine synthesizing enzyme gene
expression in human pheochromocytoma. Eur J Endocrinol 138: 363–367
Lenders JW, Keise HR, Goldstein DS et al. ((1995)) Plasma
metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med
123: 101–109
Linnoila RI, Keiser HR, Steinberg SM, Lack EE (1990) Histopathology of
benign vs. malignant sympathoadrenal paragangliomas: clinicopathologic
51.
52.
53.
54.
study of 120 cases including unusual histologic festures. Hum Pathol 21:
1168–1180
Lloyd RV (1997) Adrenal medulla and paraganglia. In: Lechago J, Gould
VE (eds) Bloodworth's endocrine pathology, 3rd edn. Williams & Wilkins,
Baltimore, pp 417–461
Manger WM, Gifford RW Jr (1990) Pheochromocytoma. In: Laragh JH,
Brenner BM (eds) Hypertension: Pathophysiology, diagnosis and
management. Raven, New York
Mann SJ (1999) Severe paroxysmal hypertension
(pseudopheochromocytoma): understanding cause and treatment. Arch
Intern Med 159: 670–674
Mantero F, Terzolo M, Arnaldi G et al. (2000) A surgery on adrenal
incidentaloma in Italy. Study group of adrenal tumors of the Italian
Society of Endocrinology. J Clin Endocrinol Metab 85: 637–644
55.
56.
57.
58.
Matthew CGP, Easton DF, Nakamura Y, Ponder BA (1991)
Presymptomatic screening for multiple endocrine neoplasia type 2A with
linked DNA markers. Lancet 333: 7–11
Maurea S, Cuocolo A, Reynolds JS, Neumann RD, Slavatore M (1996)
Diagnostic imaging in patients with paragangliomas. Computed
tomography, magnetic resoance and MIBG scintigraphy comparison. Q J
Nucl Med 40: 365
Moll R, Barth PJ. Pathologie der Nebenniere. In M. Rothmund (Hrsg)
Endokrine Chirurgie (2000) Springer, Berlin Heidelberg New York Tokio,
pp 361–377
Mulligan LM, Kwok JBJ, Healey CA et al. (1993) Germ like mutations of
RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:
458–460
59.
60.
61.
62.
63.
Nagatsu T, Yamamoto T, Nagatsu I (1970) Partial seperation and
properties of tyrosine hydroxylase from the human pheochromocytoma.
Effect of norepinephrine. Biochim Biophys Acta 198: 210–218
Nativ O, Grant CS, Sheps SG et al. (1992 b) The clinical significance of
nuclear DNA ploidy pattern in 184 patients with pheochromocytoma.
Cancer 69: 2683–2687
Neumann HPH, Eng C, Mulligan M et al. (1995) Consequences of direct
genetic testing for germline mutations in the clinical management of
families with multiple endocrine neoplasia type 2. JAMA 274: 1149–1151
Neumann HPH, Berger DP, Sigmund G et al. (1993) Pheochromozytomas,
multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N
Engl J Med. 329: 1531–1538
Niemann S, Müller U (2000) Mutations in SDHC cause autosomal
dominant paraganglioma, type 3. Nature Genet 26: 268–270
64.
65.
66.
67.
68.
69.
Page LB, Raker JW, Berberich FR (1969) Pheochromozytoma with
predominant epinephrine secretion. Am J Med 47: 648–652
Pattarino F, Bouloux PM (1996) The diagnosis of malignancy in
pheochromocytoma. Clin Endocrinol 44: 239–241
Peaston R, Lennard T, Lai L (1996) Overnight excretion of urinary
catecholamines and metabolites in the detection of pheochromocytoma. J
Clin Endocrinol Metabol 81: 1378–1394
Peaston RT, Lai LC (1993) Biochemical detection of pheochromocytoma:
should we still be measuring urinary HMMA? J Clin Pathol 46: 734–737
Plouin PF, Degoulet P, Tugaye A (1981) Le deputage du
phéochromocytome: chez quels hypertendus? Etude sémilogique chez
2585 pyertendus dont 11 ayant un phéochromocytome. Nouv Press Med
10: 869
Proye C, Vix M, Goropoulos A, Kerlo P, Lecomte-Houcke M (1992) High
incidende of malignant pheochromocytoma in a surgical unit. 26 cases out
70.
71.
72.
73.
74.
of 100 patients operated from 1971 to (1991). J Endocrinol Invest 15:
651–663
Proye C, Racadout-Leroy N, Vix M, Vermesse B, Canaille B (1994)
Comparative secretory profiles of benign and malignant
pheochromocytomas. Ann Chir 48: 430–434
Quezado ZN, Keiser HR, Parker MM (1992) Reversible myocardial
depression after massive catecholamine release from a
pheochromocytoma. Crit Car Med 20: 549–551
Reincke M, Allolio B (1995) Das Nebenniereninzidentalom: Die Kunst
der Beschränkung in Diagnostik und Therapie. Dtsch Ärztebl 92: 764–770
Riccardi VM 1981 Von Recklinghausen neurofibromatosis. N Engl J Med
305: 1617
Richard S, Beigelmann C, Duclos JM et al. (1994) pheochromocytoma as
the first manifestation of von Hippel-Lindau disease. Surgery 116: 1076–
1081
75.
76.
77.
78.
79.
80.
Richmond J, Frazer SC, Milar DR (1961) Paroxysmal hypotension due to
an adrenaline secreting pheochromocytoma. Lancet II: 2904–2906
Ross GA, Newbould E, Thomas J et al. (1993) Plasma and urinary
catecholamine concentrations in normal and patient populations. Ann Clin
Biochem 30: 38–44
Ross NS, Aron DC (1990) Hormonal evaluation of the Patient with an
incidentally discovered adrenal mass. N Engl J Med 323: 1401–1405
Sackel SG, Manson JE, Haraw SJ, Burakoff R (1985) Watery diarrhoea
syndrome due to an adrenal pheochromocytoma secreting vasoactive
intestinal peptide. Dic Dis Sci 30: 1201–1207
Saeger W (2000) Histopathological classification of adrenal tumours. Eur
J Clin Invest 30: 58–62
Saeger W, Fassnacht MC, Beuschlein F et al. (2001) Ex-vivo biopsies of
adrenal lesions: Morphology of 231 cases. Exp Clin Endocrinol Diab 109:
S19
81.
82.
83.
84.
Schmedtje JF Jr, Sax S, Pool JL, Goldfar RA, Nelson EB (1987)
Localisation of ectopic pheochromocytomas by magnetic resonance
imaging. Am J Med 83: 77 0–772
Schröder S, Niendorf A, Achilles E, Dietel M, Padberg BC et al. (1990)
Immunocytochemical differenzial diagnosis of adrenocortical neoplasms
using the monoclonal antibody D11. Virchows Arch Pathol Anat
Histopathol 417: 89–96
Shapiro B, Sisson JS, Eyre P, Copp JE, Dmuchowski C, Beierwaltes WH
(1985) 131I-MIBG – a new agent in diagnosis and treatment of
pheochromocytoma. Cardiology 72: 137–142
Sinclair D, Shenkin A, Lorimer AR (1991) Normal catecholamine
production in a patient with a paroxysmally secreting pheochromocytoma.
Ann Clin Biochem 28: 417–419
85.
86.
87.
88.
89.
Sjoberg RJ, Simic KJ, Kidd GS (1992) The clonidine suppression test for
pheochromocytoma: a review of its utility and pitfalls. Arch Intern Med
152: 1193–1197
Smith AM (1973) Pheochromocytoma and pregnancy. J Obstet Gynecol
Sprung J, O'Hara JF Jr, Gills IS et al. (2000) Anesthetic aspects of
laparoscopic and open adrenalectomy for pheochromocytoma. Urology 55:
339–343
Stenstrom G, Svardsudd K (1986) Pheochromocytoma in Sweden 1958–
1981: an analysis of the National Cancer Registry Data. Acta Med Scan
220: 225–232
Stenstrom G, Sjöström L, Smith U (1984) Diabetes mellitus in
pheochromocytoma: fasting blood glucose levels before and after surgery
in 60 patients with pheochromocytoma. Acta Endocrinol 106: 511
90.
91.
92.
93.
94.
Sutton MG, Sheps SG, Lie JT (1981) Prevalence of clinically unsuspected
pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc
56: 354–360
Tippett PA, Mc Ean AJ, Ackery DM (1986) A reevaluation of dopamine
excretion in pheochromocytoma. Clin Endocrinol 25: 401–410
Tischler AS (1991) The adrenal medulla and extra-adrenal paraganglia. In:
Kovacs K, Asa SL (eds) Functional endocrine pathology. Blackwell
Scientific Publ, Cambrige, pp 509
Tsushima Y, Ishizaka H, Matsumoto M (1993) Adrenal masses.
Differentiation with chemical shift, fast low – angle shot MR imaging.
Radiology 186: 705–709
Unsicker K (1993) The chromaffin cell: Paradigm in cell, developmental
and growth factor biology. J Anat 183: 207–221
95.
96.
97.
Wurtmann RJ, Axelrod J (1966) Control of enzymatic synthesis of
adrenaline in the adrenal medulla by the adrenal cortical steroids. J Biol
Chem 241: 2301
Young JB, Landsberg L (1998) Catecholamines and the adrenal medulla.
In: Wilson JD, Forster DW, Kronenberg HM, Larsen R (eds) Williams
testbook of endcrinology, 9th edn. Saunders, Philadelphia, pp 665–728
Zimmermann-Hösli MB, Ziegler WH, Bätscher A et al. (1990)
Permeabilitäts-Lungenödem bei Phäochromozytom. Schweiz Med
Wochenschr 120: 30–35
Literatur zu Kap. 23.9
1.
Robertson PW, Klidjian MB, Harding LK et al. (1967)Hypertension due to
a renin-secreting renal tumor. Am J Med 43: 963–976
2.
Kihara I (1996) Comments on different states of secretory autonomy of
juxtaglomerular cell tumors of the kidney. Intern Med 35: 239–240
3.
Corvol P, Pinet F, Galen FX et al. (1988) Seven lessons from reninsecreting tumors. Kidney Int 35 (Suppl 25): S38–S44
4.
Corvol P, Pinet F, Plouin PF et al. (1994)Renin-secreting tumors.
Endocrinol Metab Clin North Am 23: 255–270
5.
Hauger-Klevene JH (1970) High plasma renin activity in an oat cell
carcinoma. Cancer 26: 1112–1114
6.
Corvol P (1984). Tumor dependent hypertension. Hypertension 6: 593–
596
7.
Baert J, van Damme B, Oyen R et al. (1995) Juxtaglomerular cell tumor:
importance of clinical suspicion. Urol Int 54: 171–174
8.
Haab F, Duclos JM, Guyenne T et al. (1995) Renin secreting tumors:
diagnosis, conservative surgical approach and long-term results. J Urol
153: 1781–1784
Literatur zu Kap. 23.10
1.
Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin
Med 1955; 45: 3–17
2.
Katz FH. Primary aldosteronism with suppressed plasma renin activity due
to bilateral nodular adrenocortical hyperplasia. Ann Intern Med 1967; 67:
1035–1042
3.
Davies WW, Newsome HH, Wright LD, Hammond WG, Easton J, Bartter
FC. Bilateral adrenal hyperplasia as a cause of primary aldosteronism with
hypertension, hypokalemia and suppressed renin activity. Am J Med 1967;
42: 642–647
4.
Vaughan NJA, Jowett TP, Slater JDH, Wiggins RC, Lightman SL, Ma
JTC, Payne NN. The diagnosis of primary hyperaldosteronism. Lancet
1981; I: 120–125
5.
Melby JC, Dale SL, Wilson TE. 18-Hydroxy-deoxycorticosterone in
human hypertension. Circ Res 1971; (Suppl 2)28–29: 143–152
6.
7.
8.
9.
Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary
aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159–
172
Weingartner K, Gerharz EW, Bittinger A, Rosai J, Leppek R, Riedmiller
H. Isolated clinical syndrome of primary aldosteronism in a patient with
adrenocortical karzinoma. Case report and review of the literature. Urol Int
1995; 55: 232–235
Yoshimoto T, Naruse M, Ito Y, Naruse K, Ueda T, Tanabe A, Harada S,
Nishikawa T, Sasano H, Obara T, Demura H. Adrenocortical karzinoma
manifesting pure primary aldosteronism: a case report and analysis of
steroidogenic enzymes. J Endocrinol Invest 2000; 23: 112–117
Biglieri EG. Spectrum of mineralocorticoid hypertension. Hypertension
1991; 17: 251–261
10.
11.
12.
13.
Takeda Y, Furukawa K, Inaba S, Miyamori I, Mahbuchi H. Genetic
analysis of aldosterone synthase in patients with idiopathic
hyperaldosteronism J Clin Endocrinol Metab 1999; 84: 1633–1637
Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. J Clin
Endocrinol Metab 1999; 84: 4341–4344
Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM.
A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes
glucocorticoid-remediable aldosteronism and human hypertension. Nature
1992; 355: 262–265
Litchfield WR, Coolidge C, Silva P, Lifton RP, Fallo F, Williams GH,
Dluhy RG. Impaired potassium-stimulated aldosterone production: A
possible explanation for normokalemic glucocorticoid-remediable
aldosteronism. J Clin Endocrinol Metab 1997; 82: 1507–1510
14.
15.
16.
17.
18.
19.
Donovan SJ. 11 beta-Hydroxysteroid dehydrogenase: a link between the
dysregulation of cortisol metabolism and hypertension. Br J Biomed Sci
1999; 56: 215–225
Ferrari P, Krozowski Z. Role of the 11ß-hydroxysteroid dehydrogenase
type 2 in blood pressure regulation. Kidney Int 1999; 57: 1374–1381
Kulkarni JN, Mistry RC, Kamat MR, Chinoy R, Lotlikar RG. Autonomous
aldosterone-secreting ovarian tumor. Gynecol Oncol 1990; 37: 284–289
Todesco S, Terribile V, Borsatti A, Mantero F. Primary aldosteronism due
to a malignant ovarian tumor. J Clin Endocrinol Metab 1975; 41: 809–819
Flanagan MJ, Mc Donald JH. Heterotopic adrenocortical adenoma
producing primary aldosteronism. J Urol 1967; 98: 133–139
Komiya I, Koizumi Y, Kobayashi R, Kotani M, Yamada T, Maruyama Y.
Concurrent hypersecretion of aldosterone and cortisol from the adrenal
cortical adenoma. Am J Med 1979; 67: 516–518
20.
21.
22.
23.
24.
25.
Stewart PM. Mineralocorticoid hypertension. Lancet 1999; 353: 1341–
1347
Koczorek KR. Primärer Hyperaldosteronismus. Internist 1964; 5: 32–36
Conn JW. The evolution of primary aldosteronism. 1954–1967. Harvey
Lect 1967; 62: 257–291
Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on
prevalence of secondary forms of hypertension in 4429 consecutively
referred patients. J Hypertens 1994; 12: 609–615
Zarifis J, Lip GY, Leatherdale B, Beevers G. Malignant hypertension in
association with primary aldosteronism. Blood Press 1996; 5: 250–254
Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas
SA, Muller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment
of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877–885
26.
27.
28.
29.
30.
Kono T, Ikeda F, Oseko F, Imura H, Tanimura H. Normotensive primary
aldosteronism: report of a case. J Clin Endocrinol Metab 1981; 52: 1009–
1013
Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura
G. Cardiovascular complications in patients with primary aldosteronism.
Am J Kidney Dis 1999; 33: 261–266
Groth H, Vetter W, Stimpel M, Greminger P, Tenschert W, Klaiber E,
Vetter H. Adrenalectomy in primary aldosteronism: a long-term follow-up
study. Cardiology 1985; 72 Suppl 1: 107–116
Danforth DN, Orlando MM, Bartter FC, Javadpour N. Renal changes in
primary aldosteronism. J Urol 1977; 117: 140–144
Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L,
Pinto M, Heute A, Oestreicher E, Foradori A, Montero J. Primary
hyperaldosteronism in essential hypertensives: prevalence, biochemical
31.
32.
33.
34.
35.
profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863–
1867
Gordon RD. Mineralocorticoid hypertension. Lancet 1994; 344: 240–243
Vetter H, Vetter W. Regulation of aldosterone secretion in primary
aldosteronism. Horm Metab Res 1975; 7: 418–424
Young WF Jr. Primary aldosteronism: A common and curable form of
hypertension. Cardiol Rev 1999; 7: 207–214
Ferris JB, Brown JJ, Fraser R, Kay AW, Neville AM, O'Muircheartaigh
IG, Robertson JIS, Symington T, Lever AF. Hypertension with
aldosterone excess and low plasma renin: Preoperative distinction between
patients with and without adrenocortical tumour. Lancet 1970; II: 995–
1000
Aitchison J, Brown JJ, Ferris JB, Fraser R, Kay AW, Lever AF, Neville
AM, Symington T, Robertson JIS. Quadric analysis in the preoperative
distinction between patients with and without adrenocortical tumors in
36.
37.
38.
39.
hypertension with aldosterone excess and low plasma renin activity. Am
Heart J 1971; 82: 660–671
Ganguly A, Melada GA, Luetscher JA, Dowdy AJ. Control of plasma
aldosterone in primary aldosteronism. Distinction between adenoma and
hyperplasia. J Clin Endocrinol Metab 1973; 37: 765–775
Weinberger MH. Primary aldosteronism: diagnosis and sifferentiation of
subtypes. Ann Intern Med 1984; 100: 300–302
Sheaves R, Goldin J, Reznek RH, Chew SL, Dacie JE, Lowe DG, Ross RJ,
Wass JA, Besser GM, Grossman AB. Relative value of computed
tomography scanning and venous sampling in establishing the cause of
primary hyperaldosteronism. Eur J Endocrinol 1996; 134: 308–313
Biglieri EG, Kater CE. Mineralocorticoids in congenital adrenal
hyperplasia. J Steroid Biochem Mol Biol 1991; 40: 493–499
40.
41.
42.
43.
44.
45.
Lufkin EG, Katz FH, Hernan RH. Primary aldosteronism due to
hyperplasia of zona glomerulosa: failure of suppression by DOCA or
stimulation by angiotensin. Am J Med Sci 1972; 264: 367–374
Arteaga E, Klein R, Biglieri EG. Use of saline infusion test to diagnosi the
cause of primari aldosteronism. Am J Med 1985; 78: 722–727
Farese RV Jr, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R.
Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325:
1223–1227
Cushing H. The basophil adenomas of the pituitary body and their clinical
manifestations. Bull Johns Hopkins Hosp 1932; 50: 137–195
Vagnucci AH, Evans E. Cushing's disease with intermittent
hypercortisolism. Am J Med 1986; 80: 83–88
Ross EJ, Linch DC. Cushing's syndrome-killing disease: Discriminatory
value of signs and symptoms aiding early diagnosis. Lancet 1982; II: 646–
649
46.
47.
48.
49.
50.
51.
52.
Carpenter PC. Diagnostic evaluation of Cushing's syndrome. Endocrinol
Metab Clin North Am 1988; 17: 445–472
Wajchenberg BL, Mendonca B, Liberman B, Adelaide M, Pereira A,
Kirschner MA. Ectopic ACTH syndrome. J Steroid Biochem Mol Biol
1995; 53: 139–151
Weichert RF. The neural ectodermal origin of the peptide-secreting
endocrine glands. Am J Med 1970; 49: 232–241
Howlett TA, Rees LH, Besser GM. Cushing's syndrome. Clin Endocrinol
Metab 1985; 14: 911–945
Etxabe J, Vazquez JA. Morbidity and mortalità in Cushing's disease: an
epidemiological approach. Clin Endocrinol (Oxf) 1994; 40: 479–484
O'Neal LW, Kissane JM, Hartroft PM. The kidney in endocrine
hypertension. Arch Surg 1970; 100: 498–505
Greminger P, Tenschert W, Vetter W, Lüscher T, Vetter H. Hypertension
in Cushing's syndrome. Serono Symposium No50, In: Mantero F, Biglieri
53.
54.
55.
56.
EG, Edwards CRW (eds) Endocrinology of Hypertension. Academic
Press, London New York 1982; p103–110.1982
Ulick S, Wang JZ, Blumenfeld JD, Pickering TG. Cortisol inactivation
overload: A mechanism of mineralocorticoid hypertension in the ectopic
adrenocorticotropin syndrome. J Clin Endocrinol Metab 1992; 74: 963–
967
Biglieri EG, Stockigt JR, Schambelan M. Adrenal mineralocorticoids
causing hypertension. Am J Med 1972; 52: 623–632
Whitworth JA. Adrenocorticotropin and steroid-induced hypertension in
humans. Kidney Int Suppl 1992; 37: S34–S37
Saruta T, Suzuki H, Handa M et al. Multiple factors contribute to the
pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol
Metab 1986; 62: 275–279
57.
58.
59.
60.
61.
Pirpiris M, Sudhir K, Yeung S et al. Pressor responsiveness in
corticosteroid-induced hypertension in humans. Hypertension 1992; 19:
567–574
Krakoff L, Nicolis G, Amsel B. Pathogenesis of hypertension in Cushing's
syndrome. Am J Med 1975; 58: 216–220
Gomez-Sanchez CE, Gill JR Jr, Ganguly A, Gordon RD. Glucocorticoidsuppressible aldosteronism : a disorder of the adrenal transitional zone. J
Clin Endocrinol Metab 1988; 67 : 444–448
Fehm HL, Voigt KH, Lang RE et al. Paradoxical ACTH response to
glucocorticoids in Cushing's disease. N Engl J Med 1977; 297: 904–907
Orth DN, DeBold CR, DeCherney GS, Jackson RV, Alexander AN, Rivier
J, Rivier C, Spiess J, Vale W. Pituitary microadenomas causing Cushing's
disease respond to corticotropin-releasing factor. J Clin Endocrinol Metab
1982; 55: 1017–1019
62.
Kaltsas GA, Giannulis MG, Newell-Price JD et al. A critical analysis of
the value of simultaneous inferior petrosal sinus sampling in Cushing's
disease and the occult ectopic adrenocorticotropin syndrome. J Clin
Endocrinol Metab 1999; 84:487–492
Literatur zu Kap. 23.11
1.
Agner T, Almdal T, Thorsteinzson B, Agner E (1984) A reevaluation of
atrial fibrillation in thyrotoxicosis. Dan Med Bull 31: 157–159
2.
Amann K, Flechtenmacher C, Tornig J (1996) Permissive effect of PTH
on vascular wall hypertrophy of intramyocardial arteries in ecperimental
renal failure. Med Klin 91: 551–556
3.
Bahouth SW (1991) Thyroid hormones transcriptionally regulate the beta
1-adrenergic recepror gene in cultured ventricular myocytes. J Biol Chem
266: 15863–15869
4.
Barenbrock M, Hausberg M, Kosch M (1998) Effect of
hyperparathyroidism on arterial distensibility in renal transplant recipients.
Kidney Int 54: 210–215
5.
Bello I, Ruilope L, Alcaraz F et al. (1981) Pathogenesis of hypertension in
renal lithiasis. Mineral Electrol Metab 6: 302–307
6.
7.
8.
9.
10.
Benabe JE, Martinez-Maldonado M (1978) Hypercalcemie nephropathy.
Arch Intern Med 138: 777–779
Bergmann C, Schoeffter P, Stoclet JC (1987) Effects of parathyroid
hormone and antagonist on aortic cAMP levels. Can J Physiol Pharmacol
65: 2349–2353
Bernini G, Moretti A, Lonzi S, Bendinelli C, Miccoli P, Salvetti A (1999)
Renin-angiotensin-aldosterone system in primary hyperparathyroidism
before and after surgery
Campese VM (1989) Calcium, parathyroid hormone and blood pressure.
Am J Hypertens 2: 34–44
Ciulla M, Arosio M, Barelli MV et al. (1999) Blood pressure-independent
cardiac hypertrophy in acromegalic patients. J Hypertension 17: 1965–
1969
11.
12.
13.
14.
15.
16.
Champlain J de, Farley L, Cousineau D, Arne-ringen MR van (1976)
Circulating cateeholamine levels in human and experimental hypertension.
Circ Res 38: 109– 114
Christensson T, Hellström K, Wengle B (1977) Blood pressure in subjeets
with hyperealcemia and primary hyperparathyroidism deteeted in a health
sereening programme. Eur J Clin Invest 7: 109–113
Christensson T, Hellström K, Wengle B (1977) Hypercalcemia and
primary hyperparathyroidism. Arch Intern Med 137: 1138–1142
Colao A, Baldelli R, Marzullo P et al. (2000) Systemic hypertension and
impaired glucose tolerance are independently correlated to the severity of
the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85: 193–199
Collip J, Clark EP (1925) Further studies on the physiological action for
parathyroid hormone. J Biol Chem 64: 485–507
Costanzo LS, Weiner IM (1974) On the hypocalciuric action of
chlorothiazide. J Clin Invest 54: 628–637
17.
18.
19.
20.
21.
Crowley WF, Ridgway EC, Bough EW, Francis GS, Daniels GH,
Kourides IA, Myers GS, Maloof F (1977) Noninvasive evaluation of
cardiac function in hypothyroidism. Response to gradual thyroxine
replacement. N Engl J Med 296: 1–6
Cuocolo A, Nicolai E, Fazio S et al. (1995) Impaired left ventricular
diastolic filling in patients with acromegaly: assessment with radionuclide
angiography. J Nucl Med 36: 196–201
DeGroot WJ, Leonard JJ (1970) Hyperthyroidism as a high cardiac output
state. Am Heart J 79: 265–275
Dluhy RG (1998) Uncommon forms of secondary hypertension in older
patients. Am J Hypertension 11: 52S–56S
Douglas WW, Rubin RP (1963) The meehanism of catecholamine release
from the adrenal medulla and the role of calcium in stimulus-secretion
coupling. J Physiol (Lond) 167: 288–310
22.
23.
24.
25.
26.
Dominiczak AF, Lyall F, Morton JJ et al. (1990) Blood pressure, left
ventricular mass and intracellular calcium in primary hyperparathyroidism.
Clin Sci 789: 127–132
Drucke TB. A clinical approach to the uraemic patient with extraskeletal
calcifications. Nephrol Dial Transplant 11: 37–42
Drvota V, Janson A, Norman C et al. (1995) Evidence for the presence of
functional thyrotropin receptor in cardiac muscle. Biochem Biophys Res
Commun 211: 426–431
Duprez DA, De Buyzere ML, Verloove HH (1996) Influence of the
arterial blood pressure and nonhemodynamic factors on regional arterial
wall properties in moderate essential hypertension. J Human Hypertens 10:
251–256
Ejerblad S (1979) Uraemic myocardial disease. An experimental study,
with special reference to the effect of parathyroidectomy. Acta Chir Scand
145: 345–353
27.
28.
29.
30.
31.
32.
Ellyn FM, Kumar Y, Somberg JC (1992) Hypothyroidism complicated by
angina pectoris: therapeutic approaches. J Clin Pharmacol 32: 843–847
Erbel R, Mortasawi A, Kramer G, Oelert H, Mejer J (1989) Das
Mitralklappenprolaps-Syndrom. Dtsch Med Wochenschr 114: 678–687
Fardella C, Rodriguez-Portales JA (1995) Intracellular calcium and blood
pressure: Comparison between primary hyperparathyroidism and essential
hypertension. J Endocrinol Invest 18: 827–832
Fischer MR, Spes CH, Huss R, Gärtner R (1997) Immunogene
Hyperthyreose mit hyperdynamischem Herzversagen und beginnendem
zirrhotischem Umbau der Leber. Dtsch Med Wochenschr 122: 323–327
Fuller H, Spitell JA, McLonahey WM (1965) Myedema, a cause of
reversible hypertension. Circulation 31: 91–92
Gairard A, Pernot F, Bergmann C, v Overloop B (1994) Ions, parathyroids,
and genetic hypertension. Am J Med Sci 307: S126–129
33.
34.
35.
36.
37.
Gay RG, Raya TE, Lancaster LD, Lee RW, Morkin E, Goldman S (1988)
Effects of thyroid state on venous compliance and left ventricular
performance in rats. Am J Physiol 254: H81-H88
Gennari C, Nami R, Gonelli S (1995) Hypertension and primary
hyperparathyroidism: The role of adrenergic and renin-angiotensinaldosterone systes. Miner Electrolyte Metab 21: 77–81
George JM, Rabson AS, Ketcham A, Bartter FC (1965) Calcareous renal
disease and hyperparathyroidism. Q J Med 34: 291–301
Goldman S, Olajos M, Morkin E (1984) Control of cardiac output in
thyrotoxic calves. Evaluation of changes in the systemic circulation. J Clin
Invest 73: 358–365
Goldsmith DJ, Covic AC, Venning MC (1997) Ambulatory blood pressure
monitoring in renal dialysis and transplant patients. Am J Kidney dis 29:
593–600
38.
39.
40.
41.
42.
Gotzsche LB (1994) L-triiodothyronine acutely increases Ca2+-uptake in
the isolated, perfused rat heart. Changes in L-type Ca2+-channels and βreceptors during short- and long-term hyper- and hypothyroidism. Eur J
Endocrinol 130: 171–179
Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW (1992)
Interrelationships between the renin-angiotensin-aldosterone and calcium
homeostatic systems. J Clin Endocrinol Metab 75: 988–992
Hammond HK, White FC, Buxton IL et al. (1987) Increased myocardial βreceptors and adrenergic responses in hyperthyroid pigs. Am J Physiol
252: H283–289
Hanson AS, Linas SL (1994) Parathyroid hormone/adenylate cyclase
coupling in smooth muscle cells. Hypertension 23: 468–475
Hellström J, Birke G, Edvall CA (1958) Hypertension in
hyperparathyroidism. Br J Urol 30: 13–24
43.
44.
45.
46.
47.
48.
Hellermann J, Treese N, Mohr-Kahaly S, Beyer J, Kahaly G (1994)
Kardiopulmonale Belastung bei Hyperthyreose. Z Kardiol 83: 38–43
Hulter HN, Melby JC, Peterson JC (1986) Chronic continous PTH infusion
results in hypertension in normal subjects. J Clin Hypertens 2: 360–370
Ibels LS, Afrey AC, Huffer WE (1979) Arterial calcification and
pathology in uremic patients undergoing dialysis. Am J Med 66: 790–796
Iwasaki T, Naka M, Hiramatsu K, Yamada T, Niwa A, Aizawa T,
Murakami M, Ishihara M, Miyahara Y (1989) Echocardiographic studies
on the relationship between atrial fibrillation and atrial enlargement in
patients with hyperthyroidism of Graves´ disease. Cardiology 76: 10–17
Jespersen B, Brock A, Charles P et al. (1993) Unchanged noradrenaline
reactivity and blood pressure after corrective surgery in primary
hyperparathyroidism. Scand J Clin Lab Invest 53: 479–486
Jespersen B, Randlov A, Abrahamsen J (1997) Effects of PTH (1–34) on
blood pressure, renal function, and hormones in essential hypertension: the
49.
50.
51.
52.
53.
altered pattern of reactivity may counteract raised blood pressure. Am J
Hypertens 10: 1356–1367
Jorde R, Bonaa KH (2000) Calcium from dairy products, vitamin D intake,
and blood pressure: the Tromso study. Am J Clin Nutr 71: 1530–1535
Kahaly G, Mohr-Kahaly S, Beyer J, Meyer J (1995) Left ventricular
function analyzed by Doppler and echocardiographic methods in shortterm hypothyroidism. Am J Cardiol 75: 645–648
Kahaly G, Mohr-Kahaly S, Beyer J, Meyer J (1995) Prevalence of
myxomatous mitral valve prolaps in patients with lymphocytic thyroidits.
Am J Cardiol 76: 1309–1310
Kahaly G, Hellermann J, Mohr-Kahaly S, Treese N (1996) Impaired
cardiopulmonary exercise capacity in hyperthyroidism. Chest 109: 57–61
Kahaly G, Nieswandt J, Mohr-Kahaly S (1998) Cradiac risks of
hyperthyroidism in the elderly. Thyroid 8: 1165–1169
54.
55.
56.
57.
58.
Kawashima H (1990) Parathyroid hormone causes a transient rise in
intracellular ionized calcium in vascular smooth muscle cells. Biochem
Biophys Res Commun 166: 709–714
Klein I, Levey GS (1984) Unusual manifestation if hypothyroidism. Arch
Intern Med 144: 123–128
Klein I, Ojamaa K (1994) Editorial: Thyroid hormone and the
cardiovascular system: from theory to practice. J Clin Endocrinol Metabol
78: 1026–1027
Klüglich M, Middeke M (1992) Zirkadiane Blutdruckrhythmik bei
Hyperthyreose und primärem Hyperparathyreoidismus. Zschr Kardiol 81:
33–36
Lavin IN (1989) Mechanism of action of thyroid hormone. In: DeGroot LJ
(Hrsg) Endocrinology, vol 1. Saunders, Philadelphia London Toronto, pp
562–573
59.
60.
61.
62.
63.
Levey GS, Klein I (1990) Catecholamine.thyroid hormone interactions and
the cardiovascular manifestations of hyperthyroidism. Am J Med 88: 642–
646
Levine SA, Sturgis CC (1924) Hyperthyroidism masked a heart disease.
Boston Med Surg J 190: 233–237
Lewanczuk RZ, Pang PTK (1993) Expression of parathyroid hypertensive
factor in hypertensive primary hyperparathyroid patients. Blood Press 2:
22–27
Lind L, Palmer M, Grimelin L, Akerström G, Ljunghall S (1991)
Hypertension in primary hyperparathyroidism in relation to
histopathology. Eur J Surg 157: 457–459
Lombardi G, Colao A, Cuocolo A, Longobardi S, Di Somma C, Orio F,
Merola B, Nicolai E, Salvatore M (1997) Cardiological aspects of the
groth hormone and insulin-like growth factor I. J Ped Endocrinol Metab
10: 553–560
64.
65.
66.
67.
68.
69.
Lombardi G, Colao A, Marzullo P et al. (1997) Is growth hormone bad for
your heart ? Cardiovascular impact of GH deficiency and of acromegaly. J
Endocrinol 155: S33–37
Lopez-Valesco R, Escobar-Morreale HF, Vega B et al. (1997) Cardiac
involvement in acromegaly: Specific cardiomyopathy or consequence of
systemic hypertension ? J Clin Endocrinol Metab 82: 1047–1053
Louis WJ, Doyle AE, Anavekar 5 (1973) Plasma norepinephrine levels in
essential hypertension. N Engl J Med 288: 599–601
Lüderitz B (1982) Zur Kardiologie der Hyper- und Hypothyreose. Akt
Endokr Stoffw 3: 89–94
Magyar CE, Wang J, Azuma KK, McDonough AA (1995) Reciprocal
regulation of cardiac Na-K-ATPase and Na/Ca-exchanger: hypertension,
thyroid hormone, development. Am J Physiol 269: C675–682
Maheswaran R, Reevers DG (1989) Clinical correlates in parathyroid
hypertension. J Hypertens 7: 190–192
70.
71.
72.
73.
74.
Marks AR, Choong CY, Sanfilippo AJ, Ferre M, Weymann AE (1989)
Identifikation of high-risk and low-risk subgroups of patients with mitralvalve prolapse. New Engl J Med 320: 1031–1036
Martin WH, Spina RJ, Korte E et al. (1991) Mechanisms of impaired
exercise capacity in short duration experimental hyperthyroidism. J Clin
Invest 88: 2047–2053
Massfelder T, Parekh N, Endlich K (1996) Effect of intrarenally infused
parathyroid hormone-related protein on renal blood flow and glomerular
filtration rate in the anaesthetized rat. Br J Pharmacol 118: 1995–2000
Mathews LS, Enmberg B, Norstedt G (1989) Regulation of rat growth
hormone receptor gene expression. J Biol Chem 17: 9905–9910
Minniti G, Moroni C, Jaffrain-Rea ML et al. (1998) Prevalence of
hypertension in acromegalic patients: clinical measurement vs. 24-hour
ambulatory blood pressure monitoring. Clin Endocrinol 48: 149–152
75.
76.
77.
78.
79.
Mohr-Kahaly S, Kahaly G, Meyer J (1996) Kardiovaskuläre Wirkungen
von Schilddrüsenhormonen. Z Kardiol 85: 219–231
Morfis L, Smerdely P, Howes LG (1997) Relationship between serum
parathyroid hormone levels in the elderly and 24 h ambulatory blood
pressures. J Hypertension 15: 1271–1276
Nilsson I-L, Aberg J, Rastad J, Lind L (1999) Endothelial vasodilatory
dysfunction in primary hyperparathyroidism is reversed after
parathyroidectomy. Surgery 126: 1049–1055
Northcote RJ, McFarlane P, Kesson CM, Ballantyne D (1986) Continous
24-hour electrocardiographyin thyrotoxicosis before and after treatment.
Am Heart J 112: 339–344
Ohara N, Hiramatsu K, Shigematsu S (1995) Effect of parathyroid
hormone on left ventricular diastolic function in patients with primary
hyperparathyroidism. Miner Electrolyte Metab 21: 63–66
80.
81.
82.
83.
84.
Pang PKT, Benishin CG, Lewanczuk RZ (1991) Parathyroid hypertensive
factor, a circulating factor in animal and human hypertension. Am J
Hypertens 4: 472–477
Parker JLW, Lawson DH (1973) Death from thyrotoxicosis. Lancet II:
894–896
Parry Ch (1945) Diseases of the heart, Collected work, London,
Underwood 1: 478, 1825. Quoted by Magros RH, Classic Descriptions of
Disease. 3rd ed, Springfield, Ill, Charles C Thomas, 276
Parving HH, Hansen JM, Nielsen SL, Rossing N, Munck O, Lassen NA
(1979) Mechanisms of edema formation in myxedema-increased protein
extravasation and relytively slow lymphatic drainage. New Engl J Med
301: 460–465
Pies M, Hellermann J, Treese N et al. (1995) Kardiovaskuläre Parameter
bei passagerer Kurzzeithypothyreose. Z Kardiol 84: 668–674
85.
86.
87.
88.
89.
90.
Poch E, Fernandez-Llam P, Botey A et al. (1995) Parathyroid hormone
and platelet cytosolic calcium concentration in essential hypertension.
Nephrol Dial Transplant 10: 366–371
Polikar R, Burger AG, Scherrer U, Nicod P (1993) The thyroid and the
heart. Circulation 87: 1435–1441
Quattro Vde, Chan 5 (1972) Raised plasmacatecholamines in some
patients with primary hypertension. Lancet 1: 806–809
Resnick L (1991) Calcium metabolism in hypertension and allied
metabolic disorders. Diabetes Care 14: 505–518
Rohrer D, Dillmann WH (1988) Thyroid hormone markedly increases
mRNA coding for sarcoplasmatic reticulum Ca++-ATPase in the rat heart.
J Biol Chem 263: 6941–6944
Rosenthal ED, Roy 5 (1972) Hypertension and hyperparathyroidism. Br
Med J 4: 396–397
91.
92.
93.
94.
95.
96.
Rostand SG, Sanders C, Kirk KA (1988) Myocardial calcification and
cardiac dysfunction in chronic renal failure. Am J Med 85: 651–657
Rostand SG (1997) Ultraviolet light may contribute to geographic and
racial blood pressure differences. Hypertension 30: 150–156
Rostand SG, Drucke TB (1999) Parathyroid hormone, vitamin D, and
cardiovascular disease in chronic renal failure. Kidney Int 56: 383–392
Sancho JJ, Rouco J, Riera-Vidal R (1992) Long-term effects of
parathyroidectomy for primary hyperparathyroidism on arterial
hypertension. World J Surg 16: 732–736
Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, Beug H,
Vennstrom B (1986) The c-erb-A protein is a high affinity receptor for
thyroid hormone. Nature 324: 635–640
Saussine C, Judes C, Massfelder T (1993) Stimulatory action of
parathyroid hormone on renin secretion in vitro: A study using isolated rat
97.
98.
99.
100.
kidney, isolated rabbit glomeruli and superfused dispersed rat
juxtaglomerular cells. Clin Sci 84: 11–19
Sawin CT, Geller A, Wolf PA et al. (1994) Low serum thyrotropin
concentration as a factor for atrial fibrillation in older persons. New Engl J
Med 331: 1249–1251
Schleiffer R (1992) Parathyroid hormone and genetic hypertension. Int J
Cardiol 35: 303–310
Schleiffer R, Pemot F, Jones R (1995) Endothelium is a target organ of
parathyroid secretions in genetic hypertensive rats. Horm Metab Res 27:
16–18
Schluter KD, Piper HM (1992) Trophic effects of catecholamines and
parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol
263: H1739–1746
101.
102.
103.
104.
105.
Schiffl H, Fricke H, Sitter T (1993) Hypertension secondary to early stage
kidney disease: The pathogenic role of altered cytosolic calcium (Ca2+)
homeostasis of vascular smooth muscle cells. Am J Kidney Dis 21: 51–57
Schiffl H, Sitter T, Lang SM (1997) Noradrenergic Blood pressure
dysregulation and cytosolic calcium in primary hyperparathyroidism.
Kidney Blood Press Res 20: 290–296
Sherman SI, Ladenson PW (1991) Percutaneous transluminal coronary
angioplasty in hypothyroidism. Am J Med 90: 367–370
Shirani J, Barron MM, Pierre Louis ML, Roberts WC (1993) Congestive
heart failure, dilated cardiac ventrikles, and sudden death in
hyperthyroidism. Am J Cardiol 72: 365–368
Smith TJ, Murata J, Horwitz AL (1982) Regulation of glykosaminoglykan
synthesis by thyroid hormone in vitro. J Clin Invest 70: 1066–1072
106.
107.
108.
109.
110.
111.
Smogorzewski M, Zayed M, Zhang YB (1993) Parathyroid hormone
increases cytosolic calcium concentration in adult rat cardiac myocytes.
Am J Physiol 264: 1998–2006
Steinberg AD (1968) Myxedema and coronary arterie disease. A
comparative autopsy study. Ann Intern Med 68: 338–346
Streeten DH, Anderson GH, Howland T, Chiang R, Smulyan H (1988)
Effects of thyroid funhction on blood pressure. Recognition of
hypothyroid hypertension. Hypertension 11: 78–83
Thurnheer R, Jenni R, Russi EW, Greminger P, Speich R (1997)
Hyperthyroidism and pulmonary hypertension. J Intern Med 242: 185–188
Tobian L, Chesley G (1966) Calcium content of arteriolar walls in
normotensive and hypertensive rats. Proc Soc Exp Biol Mcd 121: 340–343
Trachtman H, Chan JC, Boyle R (1995) The relationship between calcium,
phosphorus, and sodium intake, race, and blood pressure in children with
112.
113.
114.
115.
116.
renal insufficiency: a report of the Growth Failure in Children with Renal
Disease (GFRD) study. J Am Soc Nephrol 6: 126–131
Umpierrez GE, Challapalli S, Patterson C (1995) Congestive heart failure
due to reversible cardiomyopathy in patients with hyperthyroidism. Am J
Med Sci 310: 99–102
Usdin TB, Hilton J, Vertesi T (1999) Distribution of the parathyroid
hormone 2 receptor in rat: immunolocalization reveals expression by
several endocrine cells. Endocrinology 140: 3363–3371
Van Hooft IM, Grobbee DE, Frolich M (1993) Alterations in calcium
metabolism in young people at risk for primary hypertension. The dutch
hypertension and offspring study. Hypertension 21: 267–272
Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM
(1986) The c-erb-A-gene encodes a thyroid hormone receptor. Nature 324:
641–646
Wilkin TJ (1983) Hyperthyroidism and the heart. BMJ 286: 1459–1464
117.
118.
Woeber KA (1992) Thyrotoxicosis and the heart. N Engl J Med 327: 94–
98
Young EW, MacCarron DA, Morris CD (1990) Calcium regulating
hormones in essential hypertension. Importance of gender. Am J
Hypertension 3: 161–168
Literatur zu Kap. 23.12
1.
O'Brien E, Sheridan J, O'Malley K (1988) Dippers and non-dippers.
Lancet 2: 397
2.
Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini
F, Porcellati C (1990) Circadian blood pressure changes and left
ventricular hypertrophy in essential hypertension. Circulation 81: 528–536
3.
Peppard PE, Young T, Palta M, Skatrud J (2000) Prospective study of the
association between sleep-disordered breathing and hypertension. N Engl J
Med 342: 1378–1384
4.
Grote L, Ploch T, Heitmann J, Knaack L, Penzel T, Peter JH (1999) Sleeprelated Breathing Disorder Is an Independent Risk Factor for Systemic
Hypertension. Am J Respir Crit Care Med 160: 1875–1882
5.
Lavie P, Herer P, Hoffstein V (2000) Obstructive sleep apnoea syndrome
as a risk factor for hypertension: population study. BMJ 320: 479–482
6.
7.
8.
9.
Isaksson H, Svanborg E (1991) Obstructive Sleep Apnea Syndrome in
Male Hypertenisves, Refractory to Drug Therapy. Nocturnal automatic
blood pressure measurements – An aid to diagnosis? Clin Exp Hypertens
[A] Theory and Practice A13 (6 and 7): 1195–1212
Grote, L., Hedner, J., and Peter, J. H. Sleep related breathing disorder is an
independent risk factor for uncontrolled hypertension. (2000) J
Hypertension 18: 679–685
Hedner, J. and Grote, L (1998) Cardiovascular consequences of
obstructive sleep apnea. In: McNicholas WT (ed) Respiratory disorders
during sleep. European Respiratory Society Journals, Sheffield (European
Respiratory Monograph. (3), 227–265)
Anonymous (1999) Sleep-related breathing disorders in adults:
recommendations for syndrome definition and measurement techniques in
clinical research. The Report of an American Academy of Sleep Medicine
Task Force. Sleep 22: 667–689
10.
11.
12.
13.
14.
Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The
occurrence of sleep-disordered breathing among middle-aged adults. N
Engl J Med 328: 1230–1235
Zamarron C, Gude F, Otero Y, Alvarez JM, Golpe A, Rodriguez JR
(1999) Prevalence of sleep disordered breathing and sleep apnea in 50- to
70-year-old individuals. A survey. Respiration 66: 317–322
Ferini-Strambi L, Zucconi M, Castronovo V, Garancini P, Oldani A,
Smirne S (1999) Snoring & sleep apnea: a population study in Italian
women. Sleep 22: 859–864
Peter JH, Siegrist J, Podszus T, Mayer J, Sälzer K, von Wichert P (1985)
Prevalence of sleep apnea in healthy industrial workers. Klin Wochenschr
63: 807–811
Peter JH (1987) Die Erfassung der Schlafapnoe in der Inneren Medizin.
Thieme, Stuttgart
15.
Hoffstein V, Szalai JP (1993) Predictive value of clinical features in
diagnosing obstructive sleep apnea. Sleep 16: 118–122
Literatur zu Kap. 23.13
1.
Ahrens B, Müller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E,
Grof P, Lenz G, Simhandl C, Thau K, Vestergaard P, Wolf R, Möller HJ
(1995) Excess cardiovascular and suicide mortality of affective disorders
may be reduced by lithium prophylaxis. J Affect Disord 33: 67–75
2.
Benkert O, Hippius H (1998) Kompendium der Psychiatrischen
Pharmakotherapie. Springer, Berlin Heidelberg New York Tokio
3.
Berger M (1999) Affektive Erkrankungen. In: Berger (Hrsg) Psychiatrie
und Psychotherapie, Urban & Schwarzenberg, München, Wien, Baltimore,
483–566
4.
Bottlender R, Erfurth A, Hoff P, Möller HJ (1997) Mianserin-induzierte
Hypertonie 2 Wochen nach Absetzen von Tranylcypromin. Nervenarzt 68:
591–592
5.
Coulter DM, Pillans PI (1995) Hypertension with moclobemide. Lancet
346:1032
6.
7.
8.
9.
Coupland N, Wilson S, Nutt D (1997) Antidepressant drugs and the
cardiovascular system: a comparison of tricyclics and selective serotonin
reuptake inhibitors and their relevance for the treatment of psychiatric
patients with cardiovascular problems. J Psychopharmacol 11: 83–92
Davidson K, Jonas BS, Dixon E, Markowitz J H (2000) Do depression
symptoms predict early hypertension – incidence in young adults in the
CARDIA study. Arch Intern Med 160: 1495–1500
Ferguson J, Khan A, Kucharik R (1994) A placebo-controlled comparative
study of the effects of venlafaxine and imipramine on the blood pressure in
patients treated for major depression. Neuro-psychopharmacol 10 (Suppl
165)
Frasure-Smith N, Lesperance F, Talajic M (1993) Depression following
myocardial infarction: impact on 6-month survival. JAMA 270: 1819–
1861
10.
11.
12.
13.
14.
15.
Glassman AH (1998) Cardiovascular Effects of antidepressant Drugs:
Updated. J Clin Psychiat 59 Suppl 15: 13–18
Härter M (2000): Psychische Störungen bei körperlichen Erkrankungen.
Psychother Psychosom med Psychol 50: 274–286
Heßlinger B, van Calker D, Walden J (1998) Internistische Aspekte der
Behandlung mit Phasenprophylaktika. In: Hewer W, Lederbogen F (Hrsg)
Internistische Probleme bei psychiatrischen Erkrankungen. Enke,
Stuttgart, S 89–112
Hippius H (1997) Johanniskraut (Hypericum perforatum) – ein
pflanzliches Antidepressivum. MMW 139: 36–41
Kapfhammer HP (1998) Internistische Aspekte der Behandlung mit
Antidepressiva. In: Hewer W, Lederbogen F (Hrsg) Internistische
Probleme bei psychiatrischen Erkrankungen. Enke, Stuttgart, S 51–88
Lederbogen F (1998) Internistische Aspekte der Behandlung mit
Neuroleptika und Benzodiazepinen. In: Hewer W, Lederbogen F (Hrsg)
16.
17.
18.
19.
20.
Internistische Aspekte bei psychiatrischen Erkrankungen. Enke, Stuttgart,
S 113–140
Lederbogen F, Deuschle M, Heuser I (1999) Depression – ein
kardiovaskulärer Risikofaktor. Internist 40: 1119–1121
Musselman DL, Evans DL, Nemeroff CB (1998) The relationship of
depression to cardiovascular disease. Arch Gen Psychiatry 55: 580–592
Normann C, Heßlinger B, Bauer J, Berger M, Walden J (1998) Die
Bedeutung des hepatischen Cytochrom-P450-Systems für die
Psychopharmakologie. Nervenarzt 69: 944–955
Rasmussen, SL, Overo KF, Tanghoi P (1999) Cardiac Safety of
Citalopram: Prospective Trials and Retrospective Analyses. J Clin
Psychopharmacol 19: 407–415
Shapiro PA, Lesperance F, Frasure-Smith N, O´Conner CM, Baker B,
Jiang JW, Dorian P, Harrison W, Glassman AH (1999) An open-label
preliminary trial of sertraline for treatment of major depression after acute
myocardial infarction (the SADHAT Trial). Am Heart J 137: 1100–1106
Literatur zu Kap. 23.14
1.
Arngrimson R, Hayward C, Nadaud S et al. (1997) Evidence for a familial
pregnancy-induced hypertension locus in the eNOS-gene region. Am J
Hum Genet 61/2: 354–362
2.
Baker PN, Broughton-Pipkin F, Symonds EM (1992) Comparative study
of platelet angiotensin II binding in human pregnancy. Clin Sci 83: 89 ff.
3.
Broughton Pipkin F (1988) The renin-angiotensin sytem in normal and
hypertensive pregnancies. In: Rubin PC (Hrsg) Handbook of hypertension.
Vol. 10. Hypertension in pregnancy. Elsevier, Amsterdam, pp 118–151
4.
Broughton Pipkin F, Roberts JM (2000) Hypertension in pregnancy. J
Hum Hypertens 14: 705–724
5.
Brown MA, Wang J, Whitworth JA (1997) The renin-angiotensinaldosterone system in pre-eclampsia. Clin Exp Hypertens 19: 713–726
6.
7.
8.
9.
10.
Caniggia I, Grisaru-Gravnovsky S, Kuliszewsky M, Post M, Lye SJ (1999)
Inhibition of TGF-β 3 restores the invasive capability of extravillous
trophoblasts in preeclamptic pregnancies. J Clin Invest 103, 1641–1650
Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R., Hunt BJ, Parmar K,
Bewley SJ, Shennan AH, Steer PJ, Poston L (1999) Effect of antioxidants
on the occurrence of pre-eclampsia in women at increased risk: a
randomised trial. Lancet 354: 810–816
Chesley LC, Annitto JE, Cosgrove RA (1968) The familial factor in
toxemia of pregnancy. Obstet Gynecol 32: 303–311
von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA
(2000) Fall in mean arterial pressure and fetal growth restriction in
pregnancy hypertension: a meta-analysis. Lancet 355: 87–92
Davey DA, MacGillivray I (1989) The classification and definition of the
hypertensive disorders of pregnancy. Am J Obstet Gynecol 158: 892–898
11.
12.
13.
14.
15.
Dekker G, Sibai B (2001) Primary, secondary, and tertiary prevention of
pre-eclampsia. Lancet 357: 209–215
Dekker GA, Sibai B (1998) Etiology and pathogenesis of preeclampsia:
Current concepts. Am J Obstet Gynecol 179: 1359–1375
Gant NF, Daley GL, Chand S, Whalley PJ, McDonald PC (1973) A study
of angiotensin II pressor response throughout primigravid pregnancy. J
Clin Invest 52: 2682–2689
Homuth V (2001) Renin-Angiotensin-System und ANF. In: Heilmann L,
Rath W (Hrsg) Schwangerschaftshochdruck. Wissenschaftliche
Verlagsgesellschaft, Stuttgart, S 83–93
Hubel CA, Roberts JM (1999) Lipid metabolism and oxidative stress.
Genetic factors. In: Lindheimer MD, Cunningham FG, Roberts JM (eds)
Chesley's hypertension disorders in pregnancy. Appleton & Lange,
Stamford/Connecticat, pp 453–486
16.
17.
18.
19.
20.
Luft FC (2000) The preeclampsia enigma and the renin-angiotensin
system. J Mol Med 78: 63–65
Ness RB, Roberts JM (1999) Epidemiology of hypertension. In:
Lindheimer MD, Cunningham FG, Roberts JM (Hrsg) Chesley's
hypertension disorders in pregnancy. Appleton & Lange, Stamford,
Connecticat, S 43–65
Page MM, Woods RJ, Gardiner SM et al. (2000) Excessive placental
secretion of neurokinin B during the third trimester causes pre-eclampsia.
Nature 405: 797–800
Rath W (1999) Hypertensive Schwangerschaftserkrankungen. Gynäkologe
32: 432–442
Redman CWG, Sacks GP, Sargent IL (1999) Preeclampsia: An excessive
maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1180:
499–506
21.
22.
23.
24.
25.
Roberts JM, Cooper DW (2001) Pathogenesis and genetics of preeclampsia. Lancet 357: 53
Takimoto E, Ishida J, Sugiyama F, Horiguchi H, Murakami K, Fukamizu
A (1996) Hypertension induced in pregnant mice by placental renin and
maternal angiotensinogen. Science 274 : 995–998
Walker JJ (2000) Pre-eclampsia. Lancet 356: 1260–1265
Wallukat G, Homuth V, FischerT, Lindschau C, Horstkamp B, Jüpner A,
Baur E,Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft
FC (1999) Patients with preeclampsia develop agonistic autoantibodies
against the angiotensin AT1 receptor. J Clin Invest 103, 945–952
Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C,
Farrington PE, Ogasawara M, Suzumori K, Tomoda S, Berrebi S, Sasaki
M, Corvol P, Lifton RP, Lalouel JM (1993) A molecular variant of
angiotensinogen associated with preeclampsia.Nat Genet 4: 59–61
26.
Ward K, Lindheimer MD (1999) Genetic factors. In: Lindheimer MD,
Cunningham FG, Roberts JM (eds) Chesley's hypertension disorders in
pregnancy. Appleton & Lange, Stamford, Connecticat, S 431–452